SCODiA Report by MLBI Lab

Single-Cell Landscape of Cellular Changes and Interactions in Familial and Sporadic Alzheimer's Disease Brain

This report provides a single-cell resolution analysis of human brain tissue from control, familial (E280A), and sporadic Alzheimer's disease (AD) patients. We identify significant cell type population shifts, particularly astrogliosis and microglial activation towards an M2c/M2b phenotype in AD. Distinct patterns of cell-cell communication and pathway dysregulation reveal altered synaptic function, neuroinflammation, and metabolic stress, with notable differences between familial and sporadic AD. These findings underscore the complex cellular and molecular heterogeneity of Alzheimer's disease.

Contents

0. Dataset overview
1. Single-Cell RNA-seq UMAP Overview: Condition, Sample, and Cell Type Annotations
2. UMAP Visualization of Key Marker Genes and Minor Cell Type Annotation
3. Overall Celltype_subset Marker Expression Analysis
4. 뇌 조직 내 마이너 세포 유형의 개체군 분석 결과
5. Microglial Subset Population Shifts in Brain Conditions
6. 미세아교세포(Microglia) 아형 비율 분석: 질병 상태에 따른 변화
7. E280A 조건에서의 세포 간 상호작용 분석
8. Immune Checkpoint and Cell Cycle Related Cell-Cell Interactions in Human Brain across Alzheimer's Disease Conditions
9. Condition-Specific Cell-Cell Interaction Patterns in Alzheimer's Disease
10. Microglia Condition-Specific Surfaceome Markers Analysis
11. Differential Expression of Cell Cycle Genes in Alzheimer's Disease Brain
12. 뇌세포 유형별 질병 관련 유전자 온톨로지(GO) 경로 활성화 분석
13. Gene Set Enrichment Analysis (GSEA) Across Brain Cell Types in Neurodegenerative Conditions
14. Discussion
15. Query List

0. Dataset overview

Dataset Summary

Total Cells: 43,743 cells

Total Genes: 26,318 genes

Species: Human

Tissue: Brain

• Observed Columns (Metadata): orig.ident, nCount_RNA, nFeature_RNA, percent.mt, nCount_SCT, nFeature_SCT, Diagnosis, Patient, Sex, AAO, AAD, Post.mortem.time, Thal.Phase, NIA.A.A.SCORE, NIA.A.B.SCORE, NIA.A.C.SCORE, BRAAK, CERAD, Cluster.id, NIA.AA, sample, condition, celltype_major, celltype_minor, celltype_subset, accession, tissue, sample_ext, celltype_for_cci, cluster

Conditions: E280A, Control, Sporadic

• Major Cell Types: Neuron, Oligodendrocyte, Astrocyte, Microglia, unassigned
• Minor Cell Types: Neuron, Oligodendrocyte progenitor cell, Astrocyte, Oligodendrocyte, Microglia, unassigned
• Subset Cell Types: Neuron (Glutamatergic), Oligodendrocyte progenitor cell, Astrocyte, Oligodendrocyte (Mature, Myelinating), Neuron (GABAergic), Microglia (M0), Neuron (Dopaminergic), unassigned, Neuron (Adrenergic), Microglia (M2c), Microglia (M2b), Neuron (Noradrenergic), Oligodendrocyte (Mature, Non-Myelinating), Microglia (M1), Neuron (Cholinergic), Microglia (M2a), Oligodendrocyte (Immature), Neuron (Glycinergic), Neuron (Serotonergic), Motor neuron, Oligodendrocyte (Precursor cell)
• Precomputed Results: Cell-cell interaction (CCI), Differential Gene Expression (DEG), Gene Set Enrichment Analysis (GSEA), and Gene Ontology (GO/GSA) results are available per condition/sample and cell type.

1. Single-Cell RNA-seq UMAP Overview: Condition, Sample, and Cell Type Annotations

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots of single-cell RNA-seq data from human brain tissue. The UMAPs visualize the global structure of the dataset, highlighting cell-level variations. Each plot is colored by a different annotation category: condition (Control, E280A, Sporadic), sample (individual patients), celltype_major, celltype_minor, and celltype_subset. The purpose is to assess the overall quality of cell clustering, the coherence of cell type annotations, and the distribution of conditions and samples across the cellular landscape. This helps identify potential batch effects, confirm cell identity, and understand the general organization of the cellular populations.

Visual Summary

1. Overall UMAP Structure: The UMAP displays a complex, multi-branched structure, indicative of diverse cell populations. There are several large, distinct clusters and some smaller, more diffuse groups, suggesting a range of cell identities and states within the brain tissue.
2. Condition Distribution:

• The condition UMAP shows that cells from "Control" (red), "E280A" (yellow), and "Sporadic" (purple) conditions largely intermingle across many of the major clusters.
• While there is general mixing, some clusters show a slightly higher enrichment of one condition over others. For instance, the large central cluster and some adjacent arms appear to have a good mix of all three conditions. However, a smaller, distinct cluster on the far left of the main structure appears to be predominantly "E280A" cells, and some regions show slightly more "Sporadic" or "Control" representation.

3. Sample Distribution:

• The sample UMAP reveals a more pronounced sample-specific pattern compared to condition. Different colors (representing individual samples) are visibly clustered together in various regions of the UMAP.
• This suggests that while the overall cell type structure is preserved, there might be a notable sample-specific variance or 'batch effect' influencing the clustering, where cells from the same patient tend to group more closely than cells of the same condition from different patients. This is common in single-cell datasets due to biological and technical variability between samples.

4. Major Cell Type Annotation (celltype_major):

• The celltype_major UMAP shows clear segregation of the primary cell types: Neuron (light yellow), Oligodendrocyte (light green), Astrocyte (dark red), and Microglia (orange) each occupy distinct and well-separated regions of the UMAP.
• The "unassigned" cells (dark blue) also form relatively distinct clusters, indicating that they are not randomly scattered but represent coherent, yet uncharacterized, cell populations.

5. Minor Cell Type Annotation (celltype_minor):

• The celltype_minor UMAP refines the major cell types further. For example, Oligodendrocyte progenitor cells (light blue) are distinct from mature Oligodendrocytes (light green).
• The general separation observed in celltype_major is maintained, suggesting good hierarchical annotation. Neurons remain a large, diverse cluster, as do Oligodendrocytes.

6. Cell Type Subset Annotation (celltype_subset):

• The celltype_subset UMAP provides the most granular view of cell identity. It further subdivides major and minor cell types into more specific populations (e.g., various neuronal subtypes like Glutamatergic, GABAergic, Dopaminergic neurons; different microglial states like M0, M1, M2a, M2b, M2c; and various oligodendrocyte stages).
• These finer subtypes generally cluster within their broader celltype_major and celltype_minor regions, indicating a consistent and well-resolved annotation scheme from broad to granular levels. For instance, different neuronal subtypes are all found within the large neuronal cluster, and various microglial states are found within the microglial cluster.
• The "unassigned" cells remain visible as coherent clusters.

Biological Interpretation

The UMAP visualizations provide a comprehensive overview of the cellular heterogeneity in the human brain single-cell RNA-seq dataset.

1. Robust Cell Type Identification: The clear and well-separated clustering of celltype_major, celltype_minor, and celltype_subset annotations indicates that the cell type identification process has been successful and robust. Major brain cell types (neurons, glial cells) form distinct transcriptional profiles that are accurately captured by the UMAP embedding. The finer sub-clustering within each major type (e.g., specific neuronal subtypes, oligodendrocyte differentiation stages, microglial activation states) suggests that the dataset contains sufficient resolution to distinguish these biologically meaningful populations. This is critical for investigating cell-type-specific disease mechanisms.

• For example, the distinct clustering of different Microglia states (M0, M1, M2a, M2b, M2c) is particularly interesting in the context of brain diseases like Alzheimer's (E280A, Sporadic), where microglial activation and polarization play crucial roles in neuroinflammation and disease progression PubMed search: microglia Alzheimer's disease activation. Similarly, the differentiation stages of oligodendrocytes (Precursor, Immature, Mature Myelinating/Non-Myelinating) are relevant for understanding demyelination and remyelination processes in neurodegenerative disorders.

2. Dataset Complexity and Completeness: The presence of unassigned cell clusters indicates either novel cell populations not fitting existing annotations or cells with ambiguous transcriptional profiles that require further investigation. Their coherent clustering suggests they are not merely noise but represent actual cell groups.
3. Condition-Specific Trends vs. Sample Variability:

• The overall mixing of condition across many cell clusters suggests that while the disease states (E280A, Sporadic) may induce transcriptional changes within specific cell types, these changes might not be drastic enough to completely alter the fundamental identity of the cells, causing them to form entirely separate new clusters purely based on condition.
• However, the sample-specific clustering observed in the sample UMAP is a significant finding. This "batch effect" indicates that variability between individual patients (e.g., genetic background, environmental factors, post-mortem interval, tissue processing differences) has a substantial impact on the transcriptional profiles, potentially outweighing the condition-specific signals in some dimensions of the embedding. This must be carefully considered in downstream differential expression or cell-cell interaction analyses to ensure that observed differences are truly disease-related and not artifacts of sample variability. Proper normalization and batch correction methods are essential to mitigate these effects.

Annotation Notes

The quality of cell type annotations appears high, with distinct clusters for major, minor, and subset cell types. The hierarchical nature of the annotations is well-reflected in the UMAPs. The "unassigned" cells warrant further investigation to determine their identity, as they form cohesive clusters rather than diffuse noise.

Clinical or Translational Implications

Understanding the distribution of cell types across conditions is foundational for identifying disease-specific cellular changes. While sample variability is evident and needs to be addressed statistically, the clear definition of specific cell subtypes, including various microglial activation states and oligodendrocyte maturation stages, provides a strong basis for investigating their roles in E280A Alzheimer's disease and Sporadic Alzheimer's. Identifying condition-enriched regions within the UMAP, even if subtle, can guide future cell-type-specific differential expression or pathway analyses to uncover disease mechanisms. For instance, if a specific microglial M-state (e.g., M1 or M2c) is predominantly found in E280A or Sporadic clusters, it could point towards a disease-specific immune response.

2. UMAP Visualization of Key Marker Genes and Minor Cell Type Annotation

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the expression of a panel of specific marker genes (CD3D, CD4, CD8A, CD79A, MS4A1, MZB1, CD14, LYZ, FBLN1, NOTCH3, EPCAM, MUC1, CD34) across the entire single-cell RNA-seq dataset, projected onto a Uniform Manifold Approximation and Projection (UMAP) embedding. The UMAP plot also displays the celltype_minor annotation for comparison. The primary goal is to assess cell type identity and annotation quality by examining the co-localization of known markers with assigned cell clusters and to identify any distinct populations marked by these genes.

Visual Summary

The UMAP plot shows a clear separation of major cell types annotated under celltype_minor: Neurons, Astrocytes, Microglia, Oligodendrocytes, and Oligodendrocyte progenitor cells, along with an 'unassigned' cluster. The expression patterns of the selected genes highlight several specific cell populations:

• Immune Cell Markers (CD3D, CD4, CD8A, CD79A, MS4A1, MZB1): These markers for T cells (CD3D, CD4, CD8A), B cells (CD79A, MS4A1), and plasma cells (MZB1) show very low or negligible expression across almost all cells in the UMAP. This indicates a general absence or very sparse representation of these peripheral immune cell types within the sampled brain tissue, which is expected for non-pathological or minimally inflamed brain tissue.
• Myeloid/Microglial Markers (CD14, LYZ): Both CD14 and LYZ exhibit strong and localized expression within a distinct cluster that corresponds precisely with the Microglia annotation (orange cluster).

Vascular/Progenitor/Other Markers (FBLN1, NOTCH3, CD34):

• FBLN1 shows concentrated expression in a small cluster overlapping with the Oligodendrocyte progenitor cell (light green) cluster and a subpopulation of the 'unassigned' cells.
• NOTCH3 also displays specific expression in a small cluster, primarily within the Oligodendrocyte progenitor cell (light green) cluster and extending into some 'unassigned' cells.
• CD34 is prominently expressed in a localized population that largely co-localizes with the FBLN1 and NOTCH3 positive cells, primarily within the Oligodendrocyte progenitor cell cluster and part of the 'unassigned' cells.
• Epithelial Markers (EPCAM, MUC1): Similar to the lymphoid markers, EPCAM and MUC1 show minimal to no expression across the UMAP, consistent with the brain tissue context where epithelial cells are not a primary component.

Biological Interpretation

The UMAP visualization effectively validates the celltype_minor annotations for key populations and provides insights into other specific cell identities present in the dataset:

• Robust Microglial Identification: The strong and specific co-expression of CD14 and LYZ within the Microglia cluster provides excellent confidence in the accurate annotation of this myeloid cell population. CD14 is a co-receptor for lipopolysaccharide (LPS) and is commonly found on monocytes and macrophages, including a subset of microglia. LYZ encodes lysozyme, a myeloid lineage marker [1]. This confirms the presence and identity of microglia, which are the resident immune cells of the brain and play critical roles in brain health and disease [2].
• Absence of Peripheral Lymphoid and Epithelial Contamination: The very low expression of CD3D, CD4, CD8A (T cells), CD79A, MS4A1 (B cells), MZB1 (plasma cells), EPCAM, and MUC1 (epithelial cells) indicates that the single-cell suspension is largely free of significant contamination from peripheral immune cells or epithelial tissues, which are not typical components of the brain parenchyma in healthy conditions. This strengthens the purity of the brain cell population captured.
• Identification of Endothelial/Vascular and Oligodendrocyte Progenitor Cell Populations:
• The co-expression patterns of FBLN1, NOTCH3, and CD34 are particularly informative. CD34 is a well-known marker for endothelial cells and hematopoietic stem/progenitor cells [3]. NOTCH3 is crucial for arterial endothelial cell development and maintenance, and is also expressed in vascular mural cells and some oligodendrocyte lineage cells [4]. FBLN1, an extracellular matrix glycoprotein, is also associated with vascular structures [5].
• The overlap of these markers within a cluster annotated as Oligodendrocyte progenitor cell and some 'unassigned' cells suggests that this region of the UMAP likely contains a population of vascular endothelial cells, potentially along with pericytes or other mesenchymal-like cells that may have been co-isolated with the brain tissue. These cells are integral to the neurovascular unit. The partial overlap with OPCs could also suggest a subpopulation of OPCs expressing NOTCH3, which is known to play a role in their differentiation.

Annotation Notes

The visual assessment of marker gene expression largely supports the existing celltype_minor annotations, particularly for Microglia. The low expression of peripheral immune and epithelial markers suggests a high purity of brain-resident cells. However, the distinct expression patterns of FBLN1, NOTCH3, and CD34 within the Oligodendrocyte progenitor cell cluster and a portion of the 'unassigned' cluster suggest a more granular cell identity for these populations. These signals are highly indicative of vascular cells (e.g., endothelial cells, pericytes) that are often co-isolated in brain tissue single-cell preparations. Further re-annotation or sub-clustering of the 'Oligodendrocyte progenitor cell' and 'unassigned' clusters, potentially utilizing additional vascular-specific markers, could provide a more precise characterization of these cell types.

---

References:

1. LYZ (Lysozyme): GeneCards entry for LYZ: https://www.genecards.org/cgi-bin/carddisp.pl?gene=LYZ
2. Microglia function: PubMed search for "microglia brain function": https://pubmed.ncbi.nlm.nih.gov/?term=microglia+brain+function
3. CD34 (Endothelial/HSC marker): GeneCards entry for CD34: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD34
4. NOTCH3 (Endothelial/Vascular/OPC): GeneCards entry for NOTCH3: https://www.genecards.org/cgi-bin/carddisp.pl?gene=NOTCH3
5. FBLN1 (Fibulin 1): GeneCards entry for FBLN1: https://www.genecards.org/cgi-bin/carddisp.pl?gene=FBLN1

3. Overall Celltype_subset Marker Expression Analysis

[Analysis Visualization Results]...

Analysis Overview

이 분석은 단일 세포 RNA 시퀀싱 데이터에서 도출된 AnnData 객체를 사용하여, 뇌 조직 내 다양한 세포 하위 유형(celltype_subset)별 특징적인 마커 유전자 발현 패턴을 시각화합니다. 특히, plot_markers_and_expression_dot 도구를 활용하여 각 celltype_subset 그룹에서 발현되는 주요 마커 유전자들의 평균 발현량(점의 색상 강도)과 해당 유전자를 발현하는 세포의 비율(점의 크기)을 도트 플롯 형태로 보여줍니다. 이 분석의 주요 목적은 할당된 celltype_subset 주석의 품질과 각 세포 하위 유형의 정체성을 마커 유전자 발현 패턴을 통해 확인하는 것입니다.

Visual Summary

제공된 도트 플롯은 16개의 celltype_subset 그룹(Y축)과 각 그룹을 특징짓는 수십 개의 마커 유전자(X축) 간의 발현 관계를 보여줍니다. 플롯의 각 점은 특정 세포 하위 유형 내에서 특정 유전자의 발현 수준(색상)과 발현 세포 비율(크기)을 나타냅니다.

• 세포 하위 유형별 뚜렷한 마커 패턴: 대부분의 celltype_subset 그룹은 자신에게 고유하며 높은 발현 수준과 높은 발현 세포 비율을 보이는 마커 유전자 세트를 가지고 있습니다. 이는 빨간색 사각형으로 명확하게 강조되어 있습니다.
• 아스트로사이트 (Astrocyte): GFAP, AQP4, ALDH1L1, SLC1A2 등 아스트로사이트의 특징적인 마커 유전자가 높은 발현과 높은 세포 비율로 나타나며, 다른 세포 유형에서는 거의 발현되지 않아 뚜렷한 구분을 보여줍니다.
• 미세아교세포 (Microglia): M0, M2a, M2b, M2c 서브타입 모두 AIF1, PTPRC, CSF1R, CX3CR1, TMEM119 등 일반적인 미세아교세포 마커를 공유하면서도, 각 서브타입별로 CD163 (M2a), TREM2 (M2c), IL1B (M2b) 등 뚜렷한 특이적 마커들을 발현합니다.

신경세포 (Neuron) 서브타입:

• GABA성 신경세포 (GABAergic): GAD1, GAD2, GABBR1, GABBR2와 같은 GABA 합성 효소 및 수용체 유전자들이 강력하게 발현됩니다.
• 글루탐산성 신경세포 (Glutamatergic): GLS, GRIN1, GRIN2B, SLC17A7 (VGLUT1)와 같은 글루탐산 대사 및 수용체 유전자가 특이적으로 발현됩니다.
• 콜린성 신경세포 (Cholinergic): ACHE가 매우 높은 발현 수준으로 나타나 특징적입니다.
• 다른 신경세포 서브타입(Adrenergic, Dopaminergic, Glycinergic, Noradrenergic) 또한 각자의 특정 유전자 세트를 높은 발현과 높은 세포 비율로 보여주며, 이는 해당 서브타입의 고유한 정체성을 시사합니다.

희소돌기아교세포 (Oligodendrocyte) 서브타입:

• 희소돌기아교세포 전구세포 (Oligodendrocyte progenitor cell): PDGFRA, OLIG1, OLIG2, CSPG4, SOX10 등의 전구세포 마커가 명확하게 발현됩니다.
• 성숙한 희소돌기아교세포 (Mature, Myelinating/Non-Myelinating): MBP, MOG, PLP1, TPPP와 같은 미엘린 관련 유전자가 높게 발현되며, 특히 Myelinating 서브타입에서 더 강한 패턴을 보입니다. 두 성숙 서브타입은 일부 마커를 공유하지만, 발현 강도나 패턴에서 차이를 보여 구별됩니다.

Biological Interpretation

이 마커 유전자 발현 도트 플롯은 AnnData 객체에 할당된 celltype_subset 주석의 생물학적 타당성을 강력하게 지지합니다. 각 세포 하위 유형이 고유하고 생물학적으로 의미 있는 마커 유전자 세트를 발현하는 것은, 단일 세포 RNA 시퀀싱 데이터로부터 얻은 세포 유형 분류가 정확하게 이루어졌음을 시사합니다.

• 높은 특이성 및 정체성 확인: 아스트로사이트의 GFAP GeneCards, 미세아교세포의 PTPRC (CD45) GeneCards, GABA성 신경세포의 GAD1/2 GeneCards, 글루탐산성 신경세포의 SLC17A7 (VGLUT1) GeneCards, 희소돌기아교세포의 MBP GeneCards 등은 신경과학 분야에서 잘 확립된 세포 유형 특이적 마커입니다. 이들 유전자가 해당 세포 하위 유형에서 선택적으로 고도로 발현되는 것을 통해, 데이터셋 내 세포 주석의 신뢰도를 높일 수 있습니다.
• 미세아교세포 활성화 상태 구분: M0, M2a, M2b, M2c와 같은 미세아교세포 서브타입의 분리는 염증 반응 및 조직 항상성 유지와 관련된 미세아교세포의 다양한 기능적 상태를 반영합니다. 각 서브타입이 보여주는 특이적 마커 유전자 세트는 이러한 기능적 다양성을 시사하며, 이는 뇌의 병리생리학적 연구에 중요한 기반이 됩니다.
• 신경세포의 기능적 다양성: 신경전달물질 기반으로 세분화된 신경세포 하위 유형들은 각각의 신경전달물질 대사 및 신호 전달에 관여하는 핵심 유전자를 발현하여, 뇌 기능의 복잡한 네트워크를 형성하는 데 있어 각 신경세포 유형의 고유한 역할을 명확히 합니다.
• 희소돌기아교세포의 발달 및 기능적 연속성: OPC와 성숙한 희소돌기아교세포(수초 형성 및 비수초 형성) 간의 마커 유전자 패턴은 발달 단계 및 기능적 차이를 보여주며, 이는 뇌 내 미엘린 형성 및 유지 과정에 대한 이해를 돕습니다.

Annotation Notes

이 분석 결과는 AnnData 객체에 이미 할당된 celltype_subset 주석이 해당 세포 유형의 알려진 생물학적 마커 유전자 발현 패턴과 일치함을 강력하게 보여줍니다. 이는 데이터셋 내 세포 유형 분류의 정확성과 신뢰도를 높이는 중요한 확인 과정입니다. 각 세포 하위 유형이 뚜렷하게 구별되는 마커 프로파일을 가지므로, 향후 특정 세포 유형에 대한 심층 분석의 기초가 견고함을 시사합니다. 일부 신경세포 서브타입(예: Adrenergic, Noradrenergic)의 경우, 플롯에 제시된 마커가 전통적으로 가장 널리 알려진 마커는 아닐 수 있으나, 이들 역시 해당 그룹 내에서 뚜렷하게 발현되는 특징을 보이므로, 이 데이터셋 내에서 해당 서브타입을 식별하는 데는 유효한 마커로 간주될 수 있습니다. 전반적으로, celltype_subset 주석은 마커 유전자 발현 패턴에 의해 잘 지지됩니다.

4. 뇌 조직 내 마이너 세포 유형의 개체군 분석 결과

[Analysis Visualization Results]...

Analysis Overview

제공된 막대 그래프는 인간 뇌 조직 샘플에서 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 통해 식별된 마이너 세포 유형(celltype_minor)의 상대적 개체군 분포를 보여줍니다. 샘플은 대조군(Control), E280A 변이군(E280A, 가족성 알츠하이머병 모델), 그리고 산발성 알츠하이머병(Sporadic)의 세 가지 조건으로 분류되어 있습니다. 이 분석은 각 조건 및 개별 샘플 내에서 주요 뇌 세포 유형(Neuron, Oligodendrocyte, Astrocyte, Microglia, Oligodendrocyte progenitor cell)의 상대적 풍부도를 비교합니다.

Visual Summary

1. 전반적인 세포 구성: 모든 조건에서 Neuron (주황색)과 Oligodendrocyte (옅은 노란색)가 뇌 조직에서 가장 풍부한 세포 유형으로 나타났습니다. Astrocyte (적갈색)와 Microglia (붉은 주황색), 그리고 Oligodendrocyte progenitor cell (옅은 초록색)은 상대적으로 적은 비율을 차지합니다. 'unassigned' (청록색) 세포도 소량 관찰됩니다.
2. 대조군 (Control):

• 대조군 샘플 내에서도 Neuron과 Oligodendrocyte의 상대적 비율에는 어느 정도의 이질성이 관찰됩니다 (예: Control 1, 6, 7은 Oligodendrocyte 비율이 상대적으로 높고, Control 2, 3, 4, 5, 8은 Neuron 비율이 높음).
• Astrocyte와 Microglia의 비율은 전반적으로 낮고 샘플 간 변동성이 적습니다.

3. E280A 변이군 (E280A):

• 일부 E280A 샘플(예: E280A 7, 2, 6, 1)에서는 대조군 내 Neuron 비율이 높은 샘플에 비해 Neuron의 상대적 비율이 다소 낮고 Oligodendrocyte 비율이 높아지는 경향을 보입니다.
• Astrocyte와 Microglia의 비율은 대조군과 유사하게 낮게 유지되거나, 일부 샘플에서 Astrocyte가 약간 증가하는 경향이 있습니다.

4. 산발성 알츠하이머병 (Sporadic):

• 산발성 알츠하이머병 그룹의 여러 샘플(예: Sporadic 8, 1, 2, 3, 4, 5, 7)에서 Neuron의 상대적 비율이 대조군 및 E280A 그룹에 비해 전반적으로 감소하는 경향이 뚜렷합니다.
• 동시에, Oligodendrocyte의 상대적 비율이 증가하고, 특히 Astrocyte (적갈색)의 비율이 대부분의 산발성 AD 샘플에서 대조군 및 E280A 그룹에 비해 현저히 증가하는 양상이 관찰됩니다.
• Microglia (붉은 주황색) 비율도 Sporadic 8, 1, 2, 3 샘플에서 약간 증가하는 경향을 보입니다.
• 'unassigned' 세포의 비율은 Sporadic 8 및 1에서 다른 샘플에 비해 약간 더 높게 나타났습니다.

Biological Interpretation

이 분석 결과는 알츠하이머병(AD)의 두 가지 유형인 가족성(E280A)과 산발성(Sporadic) AD에서 뇌 내 세포 구성의 변화를 시사합니다.

• 신경세포 손실 및 상대적 글리아세포 증가: 알츠하이머병의 핵심 병리인 신경세포 손실(neuronal loss)은 Neuron의 상대적 비율 감소로 나타날 수 있습니다. 특히 산발성 AD 그룹에서 Neuron 비율의 감소와 Oligodendrocyte, Astrocyte, Microglia 등 글리아세포의 상대적 증가가 관찰되는데, 이는 질병 과정에서 신경세포가 사멸하면서 글리아세포의 상대적 비율이 높아지는 현상으로 해석될 수 있습니다.
• 성상세포증(Astrogliosis) 및 신경염증(Neuroinflammation): 산발성 AD 그룹에서 Astrocyte의 현저한 증가는 성상세포증(astrogliosis)을 강력히 시사합니다. 성상세포증은 신경퇴행성 질환에서 손상에 대한 반응으로 성상세포가 증식하고 비대해지는 현상으로, 신경염증 반응의 주요 구성 요소입니다 [1]. Microglia의 미미한 증가 또한 신경염증 반응과 관련이 있을 수 있으며, 이는 AD 병리학에서 잘 알려진 특징입니다.
• 질병 유형별 차이: 가족성 AD (E280A)와 산발성 AD 간의 세포 구성 변화 양상에 미묘한 차이가 관찰됩니다. 특히, 산발성 AD에서 Astrocyte의 증가가 더 두드러지는 것은 두 질병 형태 간에 서로 다른 신경염증 또는 글리아세포 반응 경로가 존재할 가능성을 시사합니다. E280A 변이는 아밀로이드 전구 단백질(APP)의 처리를 변화시켜 Aβ 플라크 형성을 가속화하는 것으로 알려져 있으며, 이러한 초기 아밀로이드 병리가 글리아세포에 미치는 영향은 산발성 AD와 다를 수 있습니다.
• 미분류(unassigned) 세포: 일부 산발성 AD 샘플에서 'unassigned' 세포의 비율이 상대적으로 높게 나타나는 것은 기존의 잘 정의된 세포 유형으로는 설명되지 않는 새로운 질병 관련 세포 상태 또는 아형(subtype)이 존재할 가능성을 시사합니다. 이는 알츠하이머병 진행과 관련된 특정 세포 상태 변화나 새로운 세포 마커 발굴의 기회가 될 수 있습니다.

Clinical or Translational Implications

• 질병 바이오마커로서의 세포 구성: 특정 세포 유형의 상대적 풍부도 변화, 특히 Astrocyte와 Microglia 같은 글리아세포의 변화는 알츠하이머병의 진행 단계 또는 중증도를 나타내는 바이오마커로 활용될 가능성이 있습니다. 뇌 조직의 세포 구성을 정량적으로 분석하는 것은 질병 진단 및 예후 예측에 도움을 줄 수 있습니다.
• 질병 기전 이해 및 치료 표적 발굴: 산발성 AD에서 Astrocyte의 뚜렷한 증가는 신경염증 조절이 산발성 알츠하이머병의 중요한 치료 표적이 될 수 있음을 강조합니다. Astrocyte 및 Microglia의 활성화를 조절하는 약물 개발은 산발성 AD 치료에 유망한 접근법이 될 수 있습니다. E280A와 산발성 AD 간의 차이는 각 질병 유형에 최적화된 맞춤형 치료 전략을 개발하는 데 중요한 정보를 제공할 수 있습니다.
• 'unassigned' 세포의 중요성: 'unassigned' 세포에 대한 추가적인 특성 분석은 알츠하이머병에서 이전에 알려지지 않았던 새로운 세포 상태나 병리학적 메커니즘을 발견하는 데 기여할 수 있습니다. 이러한 세포들이 질병 특이적인 마커를 발현한다면, 새로운 진단 또는 치료 표적이 될 수 있습니다.

---

References:

[1] GeneCards - GFAP (Glial Fibrillary Acidic Protein, commonly used astrogliosis marker): https://www.genecards.org/cgi-bin/carddisp.pl?gene=GFAP

[2] PubMed search for "astrogliosis Alzheimer's disease neuroinflammation": https://pubmed.ncbi.nlm.nih.gov/?term=astrogliosis+Alzheimer%27s+disease+neuroinflammation

[3] PubMed search for "microglia Alzheimer's disease": https://pubmed.ncbi.nlm.nih.gov/?term=microglia+Alzheimer%27s+disease

5. Microglial Subset Population Shifts in Brain Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the relative proportions of distinct microglial subsets (M0, M1, M2a, M2b, M2c) across individual samples, grouped by three conditions: Control, E280A, and Sporadic. The data is derived from single-cell RNA sequencing of human brain tissue. This allows us to observe shifts in microglial polarization states in different disease contexts.

Visual Summary

The stacked bar plot reveals condition-specific differences in the distribution of microglial subsets:

• Control Samples: In the Control group, Microglia (M0), representing the presumed resting or homeostatic state, is overwhelmingly dominant, typically accounting for 80-95% of the total microglial population across samples. Other microglial subsets (M1, M2a, M2b, M2c) are present in very small proportions.
• E280A Samples: In the E280A condition, there is a clear reduction in the proportion of Microglia (M0) compared to controls, often ranging between 65% and 85%. Concomitantly, there is a noticeable increase in the proportion of Microglia (M2c) (teal segments), which frequently accounts for 10-20% of the microglial population. Small increases in M2a (light orange) and M2b (pale yellow) are also observed in some samples. Microglia (M1) remains minimal.
• Sporadic Samples: Similar to the E280A group, Sporadic samples also show a decreased proportion of Microglia (M0), often falling within the 60-85% range, sometimes more pronounced than E280A. There is a consistent and notable increase in Microglia (M2c) and, to a lesser extent, M2a and M2b populations, resembling the pattern seen in E280A. Microglia (M1) is generally negligible.

Biological Interpretation

Microglia are the primary immune cells of the central nervous system, exhibiting diverse functional states often broadly categorized as M1 (pro-inflammatory) and M2 (anti-inflammatory, pro-resolving, or reparative), with M0 representing a homeostatic state. The M2 category itself is heterogeneous, including M2a (wound healing, tissue repair), M2b (immunoregulatory), and M2c (deactivated, immunosuppressive, phagocytic, promoting tissue remodeling) subtypes.

1. Homeostatic vs. Activated Microglia: The dominance of Microglia (M0) in Control samples suggests a quiescent or homeostatic state in healthy brain tissue. In contrast, both E280A and Sporadic conditions show a consistent shift away from this M0 state towards activated microglial phenotypes.
2. Shift Towards M2c Polarization: The most prominent change in both E280A and Sporadic conditions is the significant increase in Microglia (M2c) populations.

• The E280A condition likely refers to the Presenilin 1 (PSEN1) E280A mutation, a well-known cause of early-onset familial Alzheimer's disease (FAD) PubMed search: PSEN1 E280A Alzheimer's disease.
• The Sporadic condition refers to sporadic Alzheimer's disease (AD), the most common form of the disease.
• M2c microglia are often characterized by their roles in phagocytosis of cellular debris, immune suppression, and tissue remodeling GeneCards: CD163 (marker for M2c). This suggests that in both familial and sporadic forms of the disease, microglia are adopting a state geared towards clearing pathological aggregates (like amyloid-beta) and potentially attempting to dampen chronic inflammation, or entering a state of dysfunction/exhaustion.

3. Minimal M1 Response: The consistently low proportion of Microglia (M1) across all conditions, including the disease states, suggests that a strong, classical pro-inflammatory (M1-driven) response may not be the primary or dominant microglial phenotype captured in these samples, at least at the subset level depicted. This doesn't rule out specific pro-inflammatory gene expression within other subsets, but the overall M1 population is not expanded.
4. Similar Microglial Response in FAD and Sporadic AD: The similar patterns of microglial polarization, particularly the increase in M2c, in both E280A (familial AD) and Sporadic (sporadic AD) conditions suggest common immune pathways and responses activated in the brain irrespective of the specific etiology of the disease. This implies a convergent pathological mechanism involving microglial activation.

Clinical or Translational Implications

The observed shifts in microglial populations hold several clinical and translational implications for neurodegenerative diseases like Alzheimer's:

1. Biomarker Potential: The relative proportions of M0 and M2c microglia could serve as potential biomarkers for disease progression or severity, differentiating diseased states from controls.
2. Therapeutic Targeting: Modulating microglial polarization offers a promising therapeutic strategy. Given the increase in M2c, interventions could focus on enhancing the beneficial phagocytic and anti-inflammatory functions of these cells, or restoring microglial homeostasis if M2c represents a dysfunctional or exhausted state PubMed search: microglia polarization Alzheimer's therapy.
3. Understanding Disease Pathogenesis: The consistent M0-to-M2c shift in both familial and sporadic AD underscores the critical role of microglial immune responses in the disease. Further research into the specific triggers and consequences of this M2c polarization could reveal novel mechanistic insights into how microglia contribute to neurodegeneration or neuroprotection. For example, investigating whether this M2c state is truly protective or becomes overwhelmed/dysfunctional over time is crucial.
4. Drug Development: The distinct microglial states identified here could represent different targets for therapeutic agents aiming to rebalance the microglial response in AD. For instance, drugs designed to specifically enhance effective phagocytosis by M2c microglia might be beneficial.

6. 미세아교세포(Microglia) 아형 비율 분석: 질병 상태에 따른 변화

[Analysis Visualization Results]...

Analysis Overview

본 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 활용하여 뇌 조직 내 미세아교세포(Microglia)의 특정 아형(M2b 및 M0) 비율이 다양한 질병 조건(Sporadic, E280A, Control)에 따라 어떻게 변화하는지 박스플롯을 통해 시각화하고 통계적 유의성을 평가한 결과입니다. 이를 통해 알츠하이머병(AD)의 산발성(Sporadic) 및 유전성(E280A) 형태에서 미세아교세포의 활성 상태 변화를 탐색합니다.

Visual Summary

제공된 박스플롯은 Microglia (M2b)와 Microglia (M0) 두 가지 아형의 세포 비율을 세 가지 조건(Sporadic, E280A, Control)에 따라 비교합니다.

Microglia (M2b) 비율:

• Sporadic 그룹에서 가장 높은 중앙값(약 7%)을 보이며, Control 그룹(중앙값 약 2%)보다 통계적으로 유의하게 높은 비율(p ≤ 0.05)을 나타냅니다.
• E280A 그룹은 중앙값 약 4%로, Sporadic과 Control 그룹의 중간 값을 보이며, 두 그룹과는 통계적으로 유의한 차이를 보이지 않았습니다 (Sporadic vs. E280A: p = 0.27, E280A vs. Control: p = 0.10).

Microglia (M0) 비율:

• Control 그룹에서 가장 높은 중앙값(약 93%)을 보이며, Sporadic 그룹(중앙값 약 77%)보다 통계적으로 유의하게 높은 비율(p ≤ 0.05)을 나타냅니다.
• E280A 그룹은 중앙값 약 86%로, Sporadic과 Control 그룹의 중간 값을 보이며, 두 그룹과는 통계적으로 유의한 차이를 보이지 않았습니다 (Sporadic vs. E280A: p = 0.24, E280A vs. Control: p = 0.14).

전반적으로 Sporadic 그룹은 Control 그룹에 비해 M2b 미세아교세포의 비율이 높고 M0 미세아교세포의 비율이 낮은 경향을 보입니다. E280A 그룹은 두 아형 모두에서 Sporadic과 Control 그룹 사이의 중간 정도의 비율을 나타냅니다.

Biological Interpretation

이러한 결과는 알츠하이머병 상태에서 미세아교세포의 활성 상태가 변화함을 시사합니다.

• M2b 미세아교세포의 증가 (Sporadic AD): M2b 미세아교세포는 다양한 신호에 의해 유도될 수 있는 독특한 활성 상태를 나타내며, 염증 반응 조절 및 조직 재형성에 관여할 수 있습니다. PubMed search: M2b microglia function Sporadic AD 환자의 뇌에서 M2b 미세아교세포의 비율이 증가했다는 것은 알츠하이머병 환경에서 미세아교세포가 단순한 염증 반응을 넘어 복합적인 역할(예: 비정상 단백질 제거, 신경 손상 복구 시도, 또는 만성 염증 유발)을 수행하고 있음을 시사합니다. 이는 알츠하이머병의 복잡한 신경염증 반응의 일환으로 해석될 수 있습니다.
• M0 미세아교세포의 감소 (Sporadic AD): M0 미세아교세포는 일반적으로 "휴지기(resting)" 또는 비활성화된 상태를 나타냅니다. PubMed search: M0 microglia Sporadic AD에서 M0 미세아교세포의 비율이 감소했다는 것은 질병 상태에서 미세아교세포가 휴지기 상태를 벗어나 활성화된 상태로 전환되었음을 의미합니다. 이는 신경퇴행성 환경에서 미세아교세포의 지속적인 활성화와 관련이 있습니다.
• E280A 그룹의 중간 표현형: E280A는 유전성 알츠하이머병(Familial Alzheimer's Disease, FAD)과 관련된 PSEN1 유전자 돌연변이로 알려져 있습니다. GeneCards: PSEN1 E280A 그룹이 M2b와 M0 미세아교세포 비율 모두에서 Sporadic과 Control 그룹 사이의 중간 값을 보이는 것은 유전성 AD와 산발성 AD 간에 미세아교세포 활성 양상에 미묘한 차이가 있거나, 질병 진행 단계 혹은 개체 간 유전적 배경의 차이를 반영할 수 있습니다.

Clinical or Translational Implications

• 질병 바이오마커로서의 가능성: 미세아교세포 아형 비율의 변화, 특히 M2b와 M0의 상대적 변화는 알츠하이머병의 진행 또는 유형(산발성 vs. 유전성)을 구별하는 잠재적인 바이오마커로 활용될 수 있습니다.
• 치료 표적 개발: Sporadic AD에서 M2b 미세아교세포의 증가는 이 아형의 미세아교세포가 질병 병리에 중요한 역할을 할 수 있음을 시사합니다. M2b 미세아교세포의 활성 또는 기능 조절은 알츠하이머병에 대한 새로운 치료 전략을 개발하는 데 중요한 표적이 될 수 있습니다. 예를 들어, 특정 미세아교세포 아형의 과도한 활성 또는 부적절한 기능은 신경 독성을 유발하거나 효율적인 병변 제거를 방해할 수 있으므로, 이를 조절하는 것이 중요할 수 있습니다.
• 유전성 vs. 산발성 AD의 차별화된 이해: 유전성(E280A) 및 산발성 AD에서 미세아교세포 활성 프로필의 차이는 두 질병 형태의 근본적인 병태생리학적 메커니즘이 다를 수 있음을 시사하며, 이는 각 유형에 맞는 맞춤형 치료 접근법의 필요성을 제기합니다.

7. E280A 조건에서의 세포 간 상호작용 분석

[Analysis Visualization Results]...

Analysis Overview

이 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 기반으로 E280A 조건(가족성 알츠하이머병 변이) 뇌 조직 내 다양한 세포 유형 간의 상호작용을 조사한 CellPhoneDB 결과입니다. 플롯은 조건별로 상위 80개 세포-세포 상호작용을 시각화하며, 각 점의 크기는 상호작용의 통계적 유의성(-log10(p-value))을 나타내고 색상은 해당 리간드-수용체 쌍의 평균 발현 수준(log2(mean))을 나타냅니다.

Visual Summary

• Neuron-Neuron 상호작용의 지배적 역할: E280A 조건에서 Neuron-Neuron 상호작용이 가장 빈번하고 강력한 시그널을 보였습니다. 특히, NRXN-NLGN (Neurexin-Neuroligin) 계열, NRXN-LRRTM (Leucine-rich repeat transmembrane neuronal protein) 계열, NRXN-CLSTN (Neurexin-Calsyntenin) 계열 등 다양한 시냅스 접착 분자 쌍에서 높은 유의성과 발현 수준을 나타냈습니다.
• 강력한 Glutamate 신호 전달: Glutamate_byGLS2_and_SLC1A1-GRM5, Glutamate_byGLS_and_SLC1A1-GRM5와 같은 Glutamate 관련 리간드-수용체 쌍이 Neuron-Neuron 상호작용에서 매우 활발하며 높은 발현을 보였습니다. 이는 E280A 뇌에서 Glutamate 신호 전달이 중요한 역할을 함을 시사합니다.
• 특정 리간드-수용체 쌍의 높은 유의성: Neuron|Neuron 간의 PTPRD-PTPRZ1 상호작용은 특히 높은 평균 발현(가장 밝은 노란색)과 높은 유의성(큰 점)을 보였습니다. 이는 시냅스 형성 및 기능에 중요한 역할을 할 수 있습니다.
• 다른 세포 유형 간의 상호작용: Oligodendrocyte progenitor cell (OPC)과 Oligodendrocyte, 또는 OPC와 Neuron 간에도 일부 NRXN-NLGN 및 Glutamate 관련 상호작용이 관찰되었습니다. Astrocyte-Astrocyte 및 Astrocyte-Neuron 상호작용에서는 C1QL-ADGRB3 쌍이 주목할 만한 유의성을 보였습니다.

Biological Interpretation

E280A 변이는 Presenilin-1 유전자에 발생하며, 이는 가족성 알츠하이머병(Familial Alzheimer's Disease, FAD)의 원인 중 하나입니다. FAD는 아밀로이드 베타(Aβ) 플라크 형성 및 시냅스 기능 이상을 특징으로 합니다.

• 시냅스 기능 이상 및 조절: Neurexin, Neuroligin, LRRTM, Calsyntenin 등은 시냅스 접착 분자로, 시냅스 형성, 안정성 및 기능에 필수적입니다 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672007/. E280A 조건에서 이러한 상호작용의 활발함은 알츠하이머병 초기 단계의 시냅스 가소성 변화 또는 손상된 시냅스 연결을 보상하려는 시도를 반영할 수 있습니다. PTPRD와 PTPRZ1은 단백질 티로신 인산화효소 수용체로 시냅스 형성 및 신경 발달에 관여하며, 이들의 강력한 상호작용은 E280A 뉴런에서 비정상적인 시냅스 재형성을 암시할 수 있습니다.
• Glutamatergic 신경전달의 교란: Glutamate는 뇌의 주요 흥분성 신경전달물질이며, 알츠하이머병에서 Glutamate 신경전달의 불균형은 흥분독성(excitotoxicity) 및 신경 세포 손상에 기여하는 것으로 알려져 있습니다 https://www.ncbi.nlm.nih.gov/books/NBK6252/. GLS2 (Glutaminase 2)는 Glutamate 합성에 관여하고, SLC1A1/2는 Glutamate 운반체이며, GRM5 (metabotropic glutamate receptor 5)는 신경 흥분성 조절에 중요합니다. E280A 뉴런 간의 강력한 Glutamate 관련 상호작용은 병리학적 Glutamate 과활성 또는 신경세포의 보상적 반응을 나타낼 수 있습니다.
• 성상교세포(Astrocyte)의 역할: C1QL (C1q-like proteins)은 시냅스 형성 및 유지에 중요한 역할을 하며, ADGRB3 (Adhesion G-protein coupled receptor B3)는 신경 발달에 관여합니다 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999718/. Astrocyte 간 및 Astrocyte-Neuron 간의 C1QL-ADGRB3 상호작용은 E280A 뇌에서 성상교세포가 시냅스 환경을 조절하거나 반응하는 데 관여할 수 있음을 시사합니다.

Clinical or Translational Implications

치료적 표적 가능성

• 시냅스 조절: NRXN-NLGN, LRRTM, CLSTN 등의 시냅스 접착 분자 경로는 알츠하이머병에서 시냅스 손상을 역전시키거나 예방하기 위한 잠재적인 치료 표적이 될 수 있습니다. 이들 분자의 기능을 조절하는 약물을 통해 시냅스 연결성을 회복하고 인지 기능을 개선할 가능성이 있습니다.
• Glutamate 시스템 조절: GRM5 수용체 또는 SLC1A1/2 운반체와 같은 Glutamate 관련 상호작용의 구성 요소를 표적으로 삼아 흥분독성을 줄이고 뉴런 손상을 완화하는 전략을 개발할 수 있습니다. 이는 기존의 알츠하이머병 치료제 개발 접근법과도 일치합니다.
• 성상교세포 매개 시냅스 지원: C1QL-ADGRB3 상호작용은 성상교세포가 시냅스 건강을 지원하는 메커니즘을 밝히고, 이 경로를 활성화하여 신경 보호 효과를 얻는 치료법 개발로 이어질 수 있습니다.
• 생체 지표 개발: E280A 조건에서 특이적으로 변화하는 이러한 리간드-수용체 상호작용의 발현 패턴은 질병 진행의 바이오마커 또는 치료 반응을 모니터링하는 데 활용될 수 있습니다.
• 실험적 검증: 이 분석에서 식별된 주요 세포-세포 상호작용 쌍은 E280A 모델 시스템(예: 환자 유래 iPSC 모델, 트랜스제닉 마우스 모델)에서 추가적인 *in vitro* 및 *in vivo* 기능 검증 실험의 강력한 후보가 됩니다. 예를 들어, 특정 NRXN-NLGN 쌍을 조작하여 시냅스 밀도, 신경망 활동, 인지 행동에 미치는 영향을 연구할 수 있습니다.

8. Immune Checkpoint and Cell Cycle Related Cell-Cell Interactions in Human Brain across Alzheimer's Disease Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) using CellPhoneDB results from single-cell RNA-seq data of human brain tissue across Control, E280A (familial Alzheimer's Disease), and Sporadic (sporadic Alzheimer's Disease) conditions. The focus is on a predefined set of genes related to immune checkpoint and cell cycle pathways. The plot_cci_dots tool visualizes significant ligand-receptor interactions between different brain cell types, with dot size representing the interaction significance (-log10(p-value)) and color representing the interaction strength (log2(mean expression)).

Visual Summary

The dot plots reveal distinct patterns of cell-cell communication involving a subset of the queried immune checkpoint and cell cycle-related genes across the three conditions:

• Prominent Interactions: The most prominent interactions across all conditions are mediated by the Transforming Growth Factor Beta (TGFB) family (TGFB1, TGFB2, TGFB3) and their receptors (TGFBR1, TGFBR2, TGFBR3), along with Epidermal Growth Factor (EGF)/EGFR and Pleiotrophin (PTN)/ALK signaling. Interactions involving other immune checkpoint or cell cycle genes from the initial query list are not prominently displayed, suggesting they either do not form significant ligand-receptor pairs or their interactions are below the n_pairs_to_show threshold for these conditions.
• Control Condition: Exhibits notable TGFB signaling primarily within glial populations (Astrocyte-Astrocyte, Microglia-Astrocyte, Astrocyte-Microglia, Microglia-Microglia) and between Oligodendrocyte progenitor cells and Astrocytes/Neurons/Microglia via PTN-ALK. EGF/EGFR interactions are less pronounced.
• E280A Condition: Shows an overall increase in the number and strength of significant interactions compared to Control. Critically, there is a marked increase in neuro-glial communication, particularly between Neuron-Microglia, Microglia-Neuron, Neuron-Astrocyte, and Astrocyte-Neuron pairs, largely driven by TGFB and EGF/EGFR signaling.
• Sporadic Condition: Presents a similar pattern to E280A, with widespread and intensified TGFB and EGF/EGFR signaling between various glial cells and neurons. A unique and significant interaction observed in the Sporadic condition is CD93-IFNGR1, specifically involving "unassigned" cells interacting with Microglia and Astrocytes.
• "unassigned" Cell Type: Consistently participates in numerous significant interactions across all conditions, indicating the potential importance of these uncharacterized cells in brain communication or highlighting the need for further cell type annotation.

Biological Interpretation

1. Dominance of TGFB and EGF/EGFR Signaling in Brain Homeostasis and Disease: The consistent and intensified presence of TGFB and EGF/EGFR signaling in both AD conditions (E280A and Sporadic) compared to Control underscores their critical roles in brain function and pathology.

• TGFB signaling is a pleiotropic pathway known to be central in inflammation, tissue repair, and cell differentiation. In the brain, it plays a key role in regulating microglial activation states, astrocyte reactivity (astrogliosis), and neuronal survival. Its widespread upregulation in AD contexts points towards increased glial activation and neuroinflammation, potentially contributing to disease progression or attempting compensatory repair mechanisms PubMed search: TGFB signaling Alzheimer's disease.
• EGF/EGFR signaling is crucial for cell proliferation, survival, and differentiation. Its heightened activity in AD conditions might reflect reactive gliosis (proliferation of astrocytes and microglia) or attempts at neurogenesis/neuronal plasticity, which can be dysregulated in AD GeneCards: EGFR.

2. Intensified Neuro-Glial Crosstalk in Alzheimer's Disease: The significant increase in interactions between Neurons, Microglia, and Astrocytes, particularly mediated by TGFB and EGF/EGFR, in both E280A and Sporadic AD suggests a robust and altered neuro-immune communication axis. This intensified crosstalk is a hallmark of the neuroinflammatory response in AD, where glia respond to neuronal stress and pathology, but can also contribute to neurotoxicity.
3. Sporadic AD-Specific Immune Signature (CD93-IFNGR1): The emergence of the CD93-IFNGR1 interaction uniquely in the Sporadic condition is a notable finding.

• CD93 (also known as C1qR1) is a C1q-binding protein involved in the complement system, phagocytosis, and inflammation, expressed on immune cells and endothelial cells GeneCards: CD93.
• IFNGR1 is the alpha chain of the interferon-gamma receptor, crucial for mediating the immune-modulatory effects of IFN-gamma, a key pro-inflammatory cytokine GeneCards: IFNGR1.
• This specific interaction suggests a distinct immune response pathway involving the complement system and IFN-gamma signaling in sporadic AD, potentially differentiating its pathology from familial forms. The involvement of "unassigned" cells in this interaction further highlights the need to characterize these cells for a complete understanding.

4. Limited Ligand-Receptor Interactions for Other Immune Checkpoint and Cell Cycle Genes: Despite a comprehensive list of target genes, many canonical immune checkpoint (e.g., PDCD1, CD274) and core cell cycle pathway genes (e.g., CDK1, CCNA2) did not appear as prominent ligand-receptor interactions in these plots. This suggests that while these genes are critical for their respective pathways, their primary roles might be intracellular, involve different interaction partners not captured, or their ligand-receptor interactions are below the significance/strength threshold in the context of these specific brain cell types and conditions.

Clinical or Translational Implications

1. Therapeutic Targeting of TGFB and EGF/EGFR Signaling: Given their pervasive involvement and upregulation in AD pathology, the TGFB and EGF/EGFR pathways represent attractive targets for therapeutic intervention. Modulating the hyperactive glial-neuronal communication via these pathways could alleviate neuroinflammation and potentially slow disease progression. However, the pleiotropic nature of TGFB signaling requires careful consideration to avoid adverse effects.
2. Biomarker and Mechanistic Insights for Sporadic AD: The unique CD93-IFNGR1 interaction in Sporadic AD offers a potential novel biomarker for distinguishing sporadic cases and provides a mechanistic avenue to investigate subtype-specific immune dysregulation. Targeting this specific interaction could offer a tailored therapeutic strategy for Sporadic AD.
3. Understanding Neuroinflammation and Glial Reactivity: The observed patterns emphasize the critical role of neuroinflammation and reactive gliosis in AD. Interventions focused on re-establishing healthy glial-neuronal interactions rather than broadly suppressing inflammation could be more effective. The specific ligand-receptor pairs identified provide concrete targets for further experimental validation in AD models.
4. Refining Cell Type Annotation: The consistent involvement of "unassigned" cells in significant CCIs underscores the importance of more precise cell type annotation. Identifying and characterizing these cells could uncover additional key players and pathways in AD pathogenesis, potentially revealing novel therapeutic targets.

9. Condition-Specific Cell-Cell Interaction Patterns in Alzheimer's Disease

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates statistically significant differences in cell-cell interactions (CCIs) among Control, E280A (a genetic form of Alzheimer's disease), and Sporadic (common form of Alzheimer's disease) conditions. The focus is on interactions involving Microglia, Astrocytes, and Oligodendrocytes, which are crucial glial cell types in the brain, along with Neurons and Oligodendrocyte Progenitor Cells (OPCs). The CellPhoneDB method was used to infer ligand-receptor interactions, and the results are visualized as a dot plot, highlighting the most significant and differentially regulated interactions.

Visual Summary

The dot plot effectively illustrates distinct patterns of cell-cell communication across the three conditions (Control, E280A, and Sporadic). Each dot represents a specific ligand-receptor pair interacting between two cell types (CCI index), with its size indicating the statistical significance (-log10(p-value), larger means more significant) and its color intensity representing the standardized mean interaction strength (darker red means stronger interaction).

• Control Condition: Characterized by a high prevalence of strong and statistically significant interactions (large, dark red dots) clustered primarily on the left side of the plot. These interactions predominantly involve Oligodendrocyte progenitor cells, Oligodendrocytes, Astrocytes, and Neurons, suggesting robust inter-cellular communication critical for brain homeostasis.
• E280A Condition: Shows a marked reduction in many of the interactions prominent in the Control group. However, a distinct set of interactions emerges as relatively stronger and more significant in E280A samples, particularly in the middle section of the plot. These interactions frequently involve Microglia, indicating a shift towards altered immune and inflammatory signaling.
• Sporadic Condition: Also exhibits a considerable deviation from the Control pattern, with a decrease in many 'healthy' interactions. Similar to E280A, Sporadic AD displays unique clusters of strong and significant interactions, predominantly on the right side of the plot. These interactions largely involve Neuron-Oligodendrocyte and Neuron-Astrocyte pairs, suggesting alterations in neuronal support and myelination.

Overall, the plot reveals a general dysregulation and re-wiring of cell-cell communication in both forms of Alzheimer's disease, with distinct signatures potentially reflecting differing underlying pathological mechanisms between E280A and Sporadic AD.

Biological Interpretation

The observed condition-specific CCI patterns provide critical insights into the pathophysiology of Alzheimer's disease in the brain.

Healthy Brain Function (Control):

• The prominent interactions in control samples highlight the intricate communication network essential for a healthy brain. Many involve Neurexin (NRXN)-Neuroligin (NLGN) and LRRTM family members (e.g., NRXN3-NLGN1 -- Oligodendrocyte progenitor cell | Oligodendrocyte, NRXN1_LRRTM4--Oligodendrocyte | Oligodendrocyte, NRXN1_NLGN3--Astrocyte | Oligodendrocyte). These molecules are well-known for their roles in synaptic organization and cell adhesion, suggesting robust structural and functional support within glial lineages and between neurons and glia. PubMed Search: Neurexin Neuroligin glial interactions
• GABAergic signaling (e.g., GABA_byGAD1_and_SLC6A11_GABBR1 -- Neuron | Oligodendrocyte) from neurons to oligodendrocytes is important for myelination and oligodendrocyte development.
• Glutamatergic signaling (e.g., Glutamate_byGLS_and_SLC1A3_GRM3 -- Oligodendrocyte progenitor cell | Oligodendrocyte) within the oligodendrocyte lineage indicates active metabolic and developmental crosstalk.
• The reduction of these interactions in AD conditions suggests a widespread disruption of fundamental neuro-glial structural and signaling integrity.

E280A (Genetic Alzheimer's Disease):

• A notable shift towards interactions involving Microglia is observed. Key interactions include:
• Integrin-mediated interactions (e.g., FBN1_integrin_a5b1_complex -- Microglia | Oligodendrocyte, L1CAM_integrin_aVb1_complex -- Microglia | Oligodendrocyte, C3_integrin_aMb2_complex -- Astrocyte | Microglia). These suggest increased extracellular matrix (ECM) remodeling, cellular adhesion, and inflammatory responses. The involvement of C3-integrin (Mac-1) in astrocyte-microglia interactions points to active complement system activation and neuroinflammation, a hallmark of AD. GeneCards: ITGAM, GeneCards: ITGB2
• Wnt signaling pathways (e.g., WNT5A_FZD6_LRP5 -- Microglia | Microglia, WNT2B_FZD3_LRP6 -- Microglia | Oligodendrocyte). Dysregulation of Wnt signaling is implicated in neuroinflammation and AD pathology. PubMed Search: Wnt signaling Alzheimer's disease glia
• Critically, the APP-SORL1 interaction (APP_SORL1 -- Microglia | Oligodendrocyte) is observed. APP is central to amyloid-beta production, and SORL1 regulates APP trafficking and Aβ clearance. This interaction directly links AD pathology to microglial and oligodendrocyte function, potentially influencing amyloid plaque formation or glial responses to plaques. GeneCards: APP, GeneCards: SORL1
• This profile indicates a strong neuroinflammatory and pathological response, consistent with the aggressive nature of genetic AD driven by amyloid pathology.

Sporadic Alzheimer's Disease:

• A distinct pattern of strong interactions, primarily involving Neuron-Oligodendrocyte communication, is observed. Key examples include:
• Neuregulin 1 (NRG1)-integrin interactions (NRG1_integrin_a6b4_complex -- Neuron | Oligodendrocyte), which are crucial for myelination and oligodendrocyte development. GeneCards: NRG1
• Interactions involving PTPRF/S, LRFN, LRRTM, FLRT2, and EFNA1/EPHA5 (e.g., PTPRF_LRFN5 -- Neuron | Oligodendrocyte, FLRT2_ADGRL1 -- Neuron | Oligodendrocyte). These protein families play roles in synaptic organization, cell adhesion, axon guidance, and neuronal plasticity. Their altered involvement suggests widespread dysregulation in neuronal-glial structural support and communication, impacting synaptic health and white matter integrity. PubMed Search: Ephrin Eph receptor neuron oligodendrocyte
• Glutamatergic signaling via metabotropic glutamate receptor 5 (Glutamate_byGLS_and_SLC1A3_GRM5 -- Neuron | Oligodendrocyte) further points to altered excitatory neuro-glial crosstalk, potentially contributing to oligodendrocyte dysfunction or excitotoxicity.
• COL19A1-integrin interactions (COL19A1_integrin_a2b1_complex -- Neuron | Oligodendrocyte) highlight the role of extracellular matrix components in mediating altered neuron-oligodendrocyte adhesion.
• This suggests significant challenges to myelin health, synaptic plasticity, and neuronal support systems, potentially reflecting different primary pathological drivers or compensatory mechanisms in sporadic AD compared to the E280A genetic form.

Clinical or Translational Implications

The identification of distinct and condition-specific cell-cell interaction patterns offers several important clinical and translational implications:

• Biomarker Discovery: The unique CCI signatures observed in E280A and Sporadic AD could serve as novel diagnostic or prognostic biomarkers. For instance, specific microglial interactions in E280A or neuron-oligodendrocyte interactions in Sporadic AD might indicate disease subtype, stage, or progression, detectable through advanced imaging or biofluid analysis.
• Therapeutic Target Identification: Understanding the dysregulated CCI pathways provides promising avenues for therapeutic intervention. Modulating microglial inflammatory signaling (e.g., integrins, Wnt pathway, APP-SORL1) in genetic AD or restoring healthy neuron-oligodendrocyte communication (e.g., NRG1, PTPRF/S pathways, glutamatergic signaling) in sporadic AD could lead to the development of targeted therapies.
• Disease Heterogeneity: The clear differences in CCI profiles between E280A and Sporadic AD underscore the molecular heterogeneity of Alzheimer's disease. This highlights the importance of precision medicine approaches, where treatment strategies are tailored to the specific pathological mechanisms predominant in different patient subgroups, rather than a 'one-size-fits-all' approach.
• Pathogenic Mechanism Elucidation: The data sheds light on the differential pathogenic mechanisms at play. E280A appears to be characterized by a strong neuroinflammatory and amyloid-related glial response, while Sporadic AD shows more pronounced alterations in structural and functional support between neurons and oligodendrocytes, potentially affecting white matter integrity and synaptic health. Further investigation into these specific interactions could uncover upstream drivers or downstream consequences critical for disease progression.

10. Microglia Condition-Specific Surfaceome Markers Analysis

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers for Microglia cells across three conditions: Control, E280A (a familial Alzheimer's disease mutation), and Sporadic (sporadic Alzheimer's disease). The results are visualized as a dot plot, where the size of each dot represents the fraction of cells expressing the marker within a given sample, and the color intensity reflects the mean expression level of the marker. This approach helps pinpoint potential surface proteins that distinguish microglial states in different disease contexts, which can be valuable for understanding disease mechanisms and identifying therapeutic targets.

Visual Summary

The dot plot effectively stratifies samples by their condition (Control, E280A, Sporadic), showing distinct sets of highly expressed surface markers for each group. The red boxes visually highlight these condition-specific marker clusters.

• Control Microglia: Samples from the "Control" group (Control 1-7) exhibit high and prevalent expression of markers such as CX3CR1, MRC1, PMEPA1, MILR1, EPHB2, and to a lesser extent, SLC29A3, SUSD3, SLC26A3, and SELPLG. CX3CR1 shows very high expression and prevalence across most control samples.
• E280A Microglia: The "E280A" group samples (E280A 1-7) are characterized by strong expression of a different set of markers, including LYVE1, DSCAM, OLR1, LINGO1, OPRM1, and PLP1. These markers show high expression and detection frequency predominantly within this condition.
• Sporadic Microglia: Samples from the "Sporadic" group (Sporadic 1-8) display elevated expression of markers like CD163, SLC2A9, ADGRE2, TNFSF13B, PLXNC1, PLB1, ESR1, and PTPRG. Similar to the other groups, these markers are largely specific to the sporadic condition.
• Cell Counts: The bar plot on the right indicates the number of microglia cells captured per sample, ranging from 43 to 176 cells. This information provides context for the robustness of marker detection within each sample.

Biological Interpretation

The distinct surfaceome marker profiles suggest that microglia adopt different functional states or undergo specific phenotypic shifts in each condition (Control, E280A, Sporadic), reflecting their varied roles in brain homeostasis and neurodegeneration.

Control Microglia: Homeostatic and Surveillance Functions

• CX3CR1: A canonical microglia marker, highly expressed in control microglia, indicating their homeostatic and surveillance functions in the healthy brain. It is crucial for microglia-neuron communication and motility [1].
• MRC1 (CD206): A mannose receptor associated with alternatively activated (M2-like) microglia, involved in phagocytosis and anti-inflammatory responses. Its presence in control microglia suggests a basal anti-inflammatory or tissue-repair phenotype, common in resting or homeostatic microglia [2].
• PMEPA1: Involved in TGF-β signaling, which plays a role in suppressing inflammation and maintaining microglial quiescence [3].
• MILR1, EPHB2, SLC29A3, SUSD3, SLC26A3, SELPLG: These genes collectively may represent a signature of non-pathological, homeostatic microglial activity, potentially involved in nutrient transport (SLC29A3, SLC26A3) or cell adhesion/signaling.

E280A Microglia: Early/Specific AD-Associated Activation

• LYVE1: Often found on perivascular macrophages and a subset of microglia, particularly those associated with vascular functions or disease-associated microglia (DAM) subtypes [4]. Its upregulation in E280A could indicate altered vascular interactions or a specific activation state related to familial AD pathogenesis.
• DSCAM (Down syndrome cell adhesion molecule): Involved in neuronal development, axon guidance, and also immune cell differentiation and function. Its expression in microglia could suggest roles in neurodevelopmental processes impacted by AD or altered microglial-neuronal interactions.
• OLR1 (LOX-1): A scavenger receptor that binds oxidized low-density lipoprotein (oxLDL) and is involved in inflammatory responses. Its upregulation points towards heightened inflammation and altered lipid metabolism in E280A microglia, consistent with AD pathology [5].
• LINGO1: Primarily known for its role in inhibiting oligodendrocyte differentiation and axonal regeneration, but also implicated in neuroinflammation and neuronal survival. Its expression in microglia might suggest cross-talk with oligodendrocytes or a role in modulating neuronal damage.
• PLP1 (Proteolipid protein 1): A major component of myelin. Its presence on microglia could indicate increased phagocytosis of myelin debris, which is a common feature in neurodegenerative diseases, or interactions with myelinating cells.
• Sporadic Microglia: Chronic Neuroinflammation and Immune Modulation
• CD163: Another marker for M2-like microglia, associated with chronic inflammation, phagocytosis of hemoglobin-haptoglobin complexes, and immune regulation. Its prominence in sporadic AD suggests a sustained anti-inflammatory or tissue-repair phenotype, potentially failing to resolve inflammation effectively [6].
• SLC2A9 (GLUT9): A glucose and uric acid transporter. Altered metabolism, including glucose utilization, is a hallmark of AD. Its upregulation might reflect metabolic adaptations or stress responses in microglia.
• ADGRE2 (EMR2): An adhesion G-protein coupled receptor involved in immune cell activation and adhesion. Its expression could indicate altered migratory patterns or interactions with other cell types in sporadic AD.
• TNFSF13B (BAFF): A B-cell activating factor. While primarily known for its role in B-cell biology, its expression in microglia could signify cross-talk with the adaptive immune system or a broader role in chronic inflammatory signaling.
• ESR1 (Estrogen receptor 1): Suggests that estrogen signaling may play a role in modulating microglial function in sporadic AD, potentially influencing inflammatory responses and neuroprotection, consistent with observed sex differences in AD prevalence [7].

The distinct marker profiles for E280A and Sporadic AD microglia underscore that while both are forms of Alzheimer's, the underlying microglial responses and associated molecular pathways may differ, reflecting distinct disease etiologies or progression patterns.

Clinical or Translational Implications

The identification of these condition-specific surfaceome markers for microglia holds significant clinical and translational potential:

• Biomarker Discovery: The unique marker sets, particularly for E280A and Sporadic AD, could serve as novel diagnostic or prognostic biomarkers. These surface proteins could be targeted for detection in biofluids (e.g., CSF) or via imaging techniques to differentiate AD subtypes or monitor disease progression.
• Therapeutic Targets: Surface markers are highly accessible targets for therapeutic interventions. Genes like OLR1 in E280A or CD163 in Sporadic AD, which are associated with inflammatory or metabolic pathways, could be explored for targeted drug development to modulate microglial activation, reduce neuroinflammation, or enhance beneficial microglial functions. For example, blocking OLR1 might reduce inflammatory lipid uptake, or modulating CD163 activity could influence phagocytosis and immune resolution.
• Precision Medicine: The differential microglial responses observed between familial (E280A) and sporadic AD highlight the potential for personalized therapeutic strategies. Treatments could be tailored to specific microglial phenotypes dominant in each disease subtype.
• Experimental Validation: These identified markers warrant further validation through techniques such as flow cytometry on isolated microglia, immunohistochemistry, or spatial transcriptomics to confirm protein expression and localization within the brain tissue. This would be crucial for establishing their utility as reliable biomarkers or therapeutic targets. Furthermore, functional studies (e.g., *in vitro* assays or *in vivo* models) could investigate the precise roles of these markers in modulating microglial behavior and AD pathogenesis.

---

References:

[1] CX3CR1 GeneCards. (GeneCards)

[2] MRC1 GeneCards. (GeneCards)

[3] PMEPA1 GeneCards. (GeneCards)

[4] LYVE1 in Microglia and Macrophages PubMed Search. (PubMed Search)

[5] OLR1 GeneCards. (GeneCards)

[6] CD163 GeneCards. (GeneCards)

[7] ESR1 GeneCards. (GeneCards)

11. Differential Expression of Cell Cycle Genes in Alzheimer's Disease Brain

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the differential expression of a curated set of cell cycle pathway-related genes across different conditions (Control, E280A, and Sporadic) in human brain tissue. The analysis specifically targeted expression within Astrocyte, Microglia, Neuron, Oligodendrocyte, and Oligodendrocyte progenitor cell populations. The boxplots display the mean expression per sample for genes identified as statistically significant, highlighting alterations in cell cycle regulation in genetic (E280A) and sporadic forms of Alzheimer's disease (AD). Due to the presentation of these specific plots, the expression levels shown represent overall trends across the aggregate of specified cell types, without explicit stratification by individual cell type in these visualizations.

Visual Summary

The boxplots illustrate the expression patterns of eight cell cycle-related genes across Control, E280A, and Sporadic conditions. Key observations include:

Upregulated Genes in AD (especially Sporadic AD):

• CCNH (Cyclin H): Shows significant upregulation in both E280A (p < 0.01) and Sporadic (p < 0.05) conditions compared to Control.
• MAD1L1 (Mitotic Arrest Deficient 1 Like 1): Significantly increased in Sporadic AD compared to both Control (p < 0.05) and E280A (p < 0.05).
• RB1 (Retinoblastoma 1): Exhibits significant upregulation in Sporadic AD relative to Control (p < 0.05).
• STAG1 (Stromal Antigen 1): Also shows significant upregulation in Sporadic AD compared to Control (p < 0.01).

Downregulated Genes in AD:

• SKP1 (S-Phase Kinase Associated Protein 1): Markedly downregulated in Sporadic AD compared to both Control (p < 0.01) and E280A (p < 0.01).
• YWHAB (14-3-3 Beta): Significantly downregulated in Sporadic AD compared to E280A (p < 0.05), with a general trend of lower expression in AD conditions.
• YWHAG (14-3-3 Gamma): Shows significant downregulation in both E280A (p < 0.01) and Sporadic (p < 0.01) conditions when compared to Control.
• YWHAH (14-3-3 Eta): Displays a pronounced and progressive downregulation across conditions, with E280A significantly lower than Control (p < 0.0001), and Sporadic significantly lower than both Control (p < 0.05) and E280A (p < 0.05).

Biological Interpretation

The observed differential expression patterns of cell cycle genes highlight significant dysregulation in both genetic (E280A) and sporadic forms of Alzheimer's disease within the brain tissue.

• Cell Cycle Re-entry and Checkpoint Activation: The upregulation of CCNH, MAD1L1, RB1, and STAG1 in AD conditions, particularly in Sporadic AD, is highly relevant.
• CCNH (Cyclin H) is a core component of the CDK-activating kinase (CAK) complex, essential for activating cyclin-dependent kinases (CDKs) that drive cell cycle progression [1]. Its upregulation suggests an increase in overall CDK activity or dysregulation of cell cycle control.
• MAD1L1 is a key component of the spindle assembly checkpoint (SAC), which monitors chromosome segregation during mitosis [2]. Its upregulation could indicate increased mitotic stress, suggesting cells are attempting to arrest the cell cycle in response to DNA damage or chromosomal instability.
• RB1 (Retinoblastoma 1) is a tumor suppressor that acts as a gatekeeper for the G1-S phase transition of the cell cycle [3]. Upregulation might signify an enhanced attempt to halt cell proliferation or a compensatory response to aberrant proliferative signals in the diseased brain.
• STAG1 is part of the cohesin complex, critical for holding sister chromatids together during cell division [4]. Its increased expression could reflect altered chromatin organization or DNA repair processes.
• In post-mitotic neurons, aberrant cell cycle re-entry (ACCR) is a well-documented pathological event in AD, often leading to neuronal death rather than successful division [5]. These gene expression changes could be indicative of ACCR in neurons or reactive proliferation in glial cells (astrocytes, microglia, OPCs).
• Disruption of Protein Degradation and Signaling: The downregulation of SKP1 and several 14-3-3 proteins (YWHAB, YWHAG, YWHAH) points to critical impairments in cellular regulatory mechanisms.
• SKP1 is a component of the SCF (SKP1-CUL1-F-box protein) ubiquitin ligase complex, which targets numerous cell cycle regulators for degradation [6]. Its downregulation in Sporadic AD could lead to the accumulation of proteins that normally drive cell division or maintain checkpoints, further contributing to cell cycle dysregulation.
• The 14-3-3 protein family (including YWHAB, YWHAG, YWHAH) are crucial adaptor proteins involved in various cellular functions, including signal transduction, cell cycle control, apoptosis, and protein trafficking [7]. They are known to interact with tau protein, influencing its phosphorylation and aggregation, which are central to AD pathology [8]. The consistent downregulation of YWHAG and YWHAH in both E280A and Sporadic AD compared to controls, with YWHAH showing a progressive decrease, is particularly striking. This widespread reduction of 14-3-3 isoforms suggests a broad impact on multiple cellular pathways, potentially impairing cellular resilience, increasing tau pathology, and affecting neuronal survival.

Clinical or Translational Implications

The observed alterations in cell cycle gene expression have several clinical and translational implications for Alzheimer's disease:

• Biomarker Potential: Genes like YWHAG and YWHAH, which show consistent and significant downregulation across both genetic and sporadic AD conditions, could serve as potential biomarkers for AD presence or progression. The distinct patterns observed between E280A and Sporadic AD for certain genes (e.g., MAD1L1, SKP1, YWHAB, YWHAH) could also help differentiate disease subtypes or stages, contributing to more precise diagnostic or prognostic tools.
• Therapeutic Targets: The dysregulated cell cycle pathways and specific proteins identified here represent potential therapeutic targets. Strategies aimed at preventing aberrant cell cycle re-entry in neurons (e.g., through modulating CCNH, RB1, or MAD1L1 activity) could protect against neurodegeneration. Restoring normal levels or function of 14-3-3 proteins could also be a viable approach to mitigate tau pathology and broader cellular dysfunction in AD [8].
• Mechanistic Insights: These findings reinforce the notion that cell cycle dysregulation is a fundamental pathological mechanism in AD. Further research into how these specific genes are perturbed and their consequences for neuronal and glial function could unveil new molecular pathways driving the disease, aiding in the development of targeted therapies.

---

References:

1. CCNH (Cyclin H) functions: GeneCards: CCNH
2. MAD1L1 (Mitotic Arrest Deficient 1 Like 1) functions: GeneCards: MAD1L1
3. RB1 (Retinoblastoma 1) functions: GeneCards: RB1
4. STAG1 (Stromal Antigen 1) functions: GeneCards: STAG1
5. Aberrant Cell Cycle Re-entry in AD: PubMed Search: "Alzheimer's disease aberrant cell cycle re-entry"
6. SKP1 (S-Phase Kinase Associated Protein 1) functions: GeneCards: SKP1
7. 14-3-3 protein family functions: GeneCards: YWHAB, GeneCards: YWHAG, GeneCards: YWHAH
8. 14-3-3 proteins and Tau in AD: PubMed Search: "14-3-3 tau Alzheimer's disease"

12. 뇌세포 유형별 질병 관련 유전자 온톨로지(GO) 경로 활성화 분석

[Analysis Visualization Results]...

Analysis Overview

이 분석은 단일 세포 RNA 시퀀싱 데이터를 사용하여 뇌 조직 내 주요 세포 유형(성상교세포, 미세아교세포, 뉴런, 희소돌기아교세포, 희소돌기아교세포 전구세포)에서 특정 질병 조건(E280A, Sporadic)과 대조군(Control) 간의 유전자 온톨로지(GO) 경로 활성화 차이를 조사합니다. 결과는 각 세포 유형에서 '대조군 대 기타 조건', 'E280A 대 기타 조건', 'Sporadic 대 기타 조건' 비교를 통해 유의미하게 상향 조절된(up) GO 용어를 점 그림(dot plot) 형태로 시각화한 것입니다. 점의 크기와 색상 강도는 통계적 유의성(-log10(P-value))을 나타냅니다.

Visual Summary

제공된 점 그림은 뇌의 주요 세포 유형(성상교세포, 미세아교세포, 뉴런, 희소돌기아교세포, 희소돌기아교세포 전구세포)에서 상향 조절된 유전자 온톨로지(GO) 경로를 보여줍니다.

• 뉴런 및 미세아교세포에서의 강력한 신호: 뉴런(Neuron)과 미세아교세포(Microglia)는 E280A 및 Sporadic 조건에서 가장 광범위하고 통계적으로 유의미한 경로 활성화를 보입니다. 이는 이들 세포 유형이 질병 상태에서 가장 큰 영향을 받거나 활성 변화를 겪음을 시사합니다.
• 신경퇴행성 질환 경로의 두드러진 활성화: "Alzheimer disease", "Parkinson disease", "Amyotrophic lateral sclerosis", "Huntington disease", "Prion disease", 그리고 일반적인 "Pathways of neurodegeneration"과 같은 신경퇴행성 질환 관련 경로들이 뉴런 및 미세아교세포에서 E280A 및 Sporadic 조건일 때 매우 유의미하게 상향 조절되어 있습니다.
• 면역 및 염증 반응: 미세아교세포는 "Fc gamma R-mediated phagocytosis"와 여러 세균/바이러스 감염 경로(예: "Salmonella infection", "Pathogenic Escherichia coli infection", "Human immunodeficiency virus 1 infection")에서 강력한 활성화를 보여, 뇌의 염증 및 면역 반응이 활발함을 나타냅니다.
• 대사 및 세포 기능 이상: 뉴런에서는 "Oxidative phosphorylation", "Protein processing in endoplasmic reticulum", "Autophagy", "Mitophagy", "Dopaminergic synapse", "Glutamatergic synapse" 등 대사, 단백질 처리, 시냅스 기능 관련 경로들이 크게 활성화되어 있습니다.
• 조건 간 유사성: E280A 조건과 Sporadic 조건은 뉴런과 미세아교세포에서 매우 유사한 GO 경로 활성화 패턴을 보여줍니다. 이는 두 질병 상태가 공유하는 병리학적 메커니즘이 있음을 시사합니다.
• 성상교세포 및 희소돌기아교세포의 상대적 차이: 성상교세포(Astrocyte), 희소돌기아교세포(Oligodendrocyte), 희소돌기아교세포 전구세포(Oligodendrocyte progenitor cell)는 뉴런 및 미세아교세포에 비해 이들 특정 경로 목록에서 유의미한 활성화가 적습니다. 이는 이들 세포 유형이 이 질병 맥락에서 다른 유형의 경로 변화를 겪거나, 이 목록에 포함되지 않은 다른 기능에 주로 영향을 받을 수 있음을 나타냅니다.

Biological Interpretation

이 분석 결과는 뇌의 E280A 및 Sporadic 조건에서 뉴런과 미세아교세포가 핵심적인 병리적 변화를 겪는다는 강력한 생물학적 증거를 제시합니다.

뉴런의 취약성 및 기능 부전:

• 신경퇴행성 경로의 핵심: 뉴런에서 알츠하이머병, 파킨슨병, ALS, 헌팅턴병, 프리온병 등 다양한 신경퇴행성 질환 경로의 동시 활성화는 E280A 및 Sporadic 조건이 광범위한 신경 손상 및 기능 부전을 유발함을 시사합니다. 이는 AnnData의 BRAAK, CERAD, NIA-ABC 점수 등 알츠하이머병 관련 병리학적 데이터와 일관됩니다.
• 에너지 대사 및 단백질 항상성 장애: "Oxidative phosphorylation"의 활성화는 미토콘드리아 기능 부전 및 에너지 대사 변화를, "Protein processing in endoplasmic reticulum"의 활성화는 ER 스트레스 및 단백질 비정상적인 폴딩을 나타냅니다. "Autophagy" 및 "Mitophagy"의 활성화는 손상된 세포 구성 요소와 미토콘드리아를 제거하려는 시도일 수 있지만, 이러한 과정의 만성적인 장애는 신경퇴행의 특징입니다 [1].
• 시냅스 기능 이상: "Dopaminergic synapse", "Glutamatergic synapse", "Long-term potentiation", "Synaptic vesicle cycle"의 활성화는 신경전달 및 시냅스 가소성의 심각한 변화를 반영하며, 이는 인지 기능 저하 및 신경 회로의 손상과 직접적으로 관련됩니다.

미세아교세포의 신경염증 및 면역 반응:

• 염증성 활성화: 미세아교세포에서 "Fc gamma R-mediated phagocytosis" 및 다양한 세균/바이러스 감염 경로의 활성화는 미세아교세포가 염증성 또는 반응성 상태로 전환되었음을 강력히 시사합니다. 이는 신경퇴행성 질환에서 관찰되는 "무균성 염증(sterile inflammation)" 또는 만성 염증 반응과 일치하며, 미세아교세포가 손상된 뉴런 구성 요소를 제거하고 신경독성 물질을 분비할 수 있음을 나타냅니다 [2].
• 단백질 처리 및 클리어런스: 미세아교세포에서의 "Autophagy" 및 "Mitophagy" 활성화는 이들 세포가 비정상적인 단백질 응집체나 세포 잔해를 제거하는 역할을 수행하려는 노력을 반영합니다.
• 질병 특이적 및 공유 메커니즘: E280A(유전성) 및 Sporadic(산발성) 조건 모두에서 유사한 경로가 활성화되는 것은 두 형태의 질병이 최종적으로 뉴런 및 미세아교세포에서 유사한 세포 병리학적 결과를 초래하거나, 공통된 근본적인 병원성 드라이버를 공유할 수 있음을 시사합니다.
• 성상교세포 및 희소돌기아교세포의 역할: 성상교세포와 희소돌기아교세포/OPC의 상대적으로 적은 신호는 이들 세포 유형이 질병 과정에서 덜 영향을 받거나, 이 분석에서 포착되지 않은 다른 기능적 변화를 겪을 수 있음을 의미합니다. 하지만 일부 신호(예: 성상교세포의 "Cholinergic synapse" 또는 희소돌기아교세포의 "Spliceosome")는 이들 세포가 특정 방식으로 질병에 반응하거나 기여할 수 있음을 나타냅니다.

Clinical or Translational Implications

이 분석 결과는 신경퇴행성 질환의 진단, 예후 및 치료 전략 개발에 중요한 시사점을 제공합니다.

• 뉴런 보호 및 기능 회복: 뉴런에서 발견된 시냅스 기능 이상, 미토콘드리아 손상, 단백질 항상성 교란 등은 신경퇴행성 질환의 주요 병리이며, 이러한 경로를 표적하는 약물 개발은 신경 보호 및 인지 기능 회복에 중요할 수 있습니다. 예를 들어, 미토콘드리아 기능을 개선하거나 단백질 응집을 줄이는 전략이 해당됩니다 [3].
• 신경염증 조절: 미세아교세포의 과도한 염증 반응은 질병 진행을 악화시킬 수 있으므로, 미세아교세포의 활성화를 조절하거나 그들의 유익한 기능을 강화하는 치료법(예: 독성 부산물 제거 능력 증진)이 유망합니다. 특히, "Fc gamma R-mediated phagocytosis"와 같은 특정 면역 경로를 조절하는 것은 신경염증을 관리하는 데 도움이 될 수 있습니다.
• 질병 스펙트럼 이해: 알츠하이머병 외에 파킨슨병, ALS 등 다른 신경퇴행성 질환 경로가 동시 활성화되는 것은 뇌 질환의 복잡성과 공유 메커니즘의 중요성을 강조합니다. 이는 단일 질병에 국한되지 않는 광범위한 신경 보호 전략 개발의 필요성을 시사합니다.
• 바이오마커 발굴: 뉴런과 미세아교세포에서 유의미하게 상향 조절된 특정 경로의 유전자들을 잠재적인 바이오마커로 활용하여 질병의 초기 진단, 진행 모니터링, 치료 반응 평가에 기여할 수 있습니다.
• 약물 재조정(Drug Repurposing): "Non-alcoholic fatty liver disease"와 같은 예상치 못한 경로의 활성화는 대사 경로 조절 약물이 뇌 질환에도 치료적 효과를 가질 수 있음을 시사하며, 기존 약물의 새로운 적용 가능성을 탐색할 기회를 제공합니다.

---

References:

[1] Nixon, R. A. (2013). The role of autophagy in neurodegenerative disease. *Nature Medicine*, 19(8), 983-997. PubMed Search: Autophagy neurodegeneration

[2] Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, R. A., Brosseron, F., Feinstein, D. L., ... & Latz, E. (2015). Neuroinflammation in Alzheimer's disease. *The Lancet Neurology*, 14(4), 388-405. PubMed Search: Neuroinflammation Alzheimer%27s disease

[3] Reddy, P. H. (2019). Abnormal mitochondrial dynamics and synaptic dysfunction in Alzheimer's disease: Implications for disease modifying therapies. *Free Radical Biology and Medicine*, 134, 461-470. PubMed Search: Mitochondrial dysfunction Alzheimer%27s synapse

13. Gene Set Enrichment Analysis (GSEA) Across Brain Cell Types in Neurodegenerative Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results, visualized as a dot plot, for five major brain cell types: Astrocytes, Microglia, Neurons, Oligodendrocytes, and Oligodendrocyte progenitor cells (OPCs). The analysis compares gene expression profiles in specific conditions (Control, E280A, Sporadic) against "others" (all other conditions/samples not in the target group for that comparison). The E280A and Sporadic conditions likely represent neurodegenerative disease states, given the AnnData context (Diagnosis column). The plot highlights pathways significantly enriched or suppressed in each cell type and condition comparison, providing insights into condition-associated biological mechanisms.

Visual Summary

The dot plot displays various Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways on the y-axis and different cell type-condition comparisons on the x-axis.

• Dot Size: The size of each dot corresponds to the statistical significance of the enrichment, represented by -log10(p-value). Larger dots indicate a more significant enrichment/suppression.
• Dot Color: The color of each dot indicates the Normalized Enrichment Score (NES). Red colors (positive NES) signify pathway enrichment (upregulation of genes within the pathway), while blue colors (negative NES) indicate pathway suppression (downregulation of genes within the pathway). A white/light gray color indicates an NES close to zero, meaning no significant enrichment or suppression. The color intensity reflects the magnitude of the NES.

Key Observations from the Plot:

• Widespread Metabolic and ER Stress Signatures: Many cell types across both E280A and Sporadic conditions show significant enrichment (red dots, positive NES) in pathways like "Oxidative phosphorylation," "Protein processing in endoplasmic reticulum," and "Ribosome." This suggests a common cellular response involving altered energy metabolism, protein folding, and protein synthesis.
• Immune and Inflammatory Responses in Microglia and Astrocytes: In both E280A and Sporadic conditions, Microglia and Astrocytes display enrichment in various immune-related and infectious disease pathways, such as "Antigen processing and presentation," "ECM-receptor interaction," "Focal adhesion," "Pathogenic Escherichia coli infection," "Herpes simplex virus 1 infection," and "Toxoplasmosis." This indicates activation of immune and inflammatory processes.
• Neuronal Dysfunction and Disease-Specific Pathways: Neurons in E280A and Sporadic conditions show enrichment in "Synaptic vesicle cycle" and "Huntington disease." The latter is particularly interesting, suggesting shared pathogenic mechanisms or pathways with other neurodegenerative disorders.
• MAPK Signaling Pathway Suppression: "MAPK signaling pathway" appears suppressed (blue dots, negative NES) in Astrocytes, Neurons, and Oligodendrocyte progenitor cells in both E280A and Sporadic conditions, suggesting a potential downregulation of proliferative, differentiation, or stress response pathways.
• Notch Signaling Pathway Variability: "Notch signaling pathway" is suppressed in Microglia in E280A but enriched in Sporadic Microglia, indicating condition-specific roles in microglial activity.
• Apoptosis and Autophagy: "Apoptosis" and "Autophagy" pathways show enrichment in Astrocytes and Microglia in both E280A and Sporadic, suggesting increased programmed cell death and cellular degradation processes.
• Oligodendrocyte Involvement: Oligodendrocytes and OPCs largely mirror the metabolic and ER stress patterns observed in other cell types ("Oxidative phosphorylation," "Protein processing in endoplasmic reticulum," "Ribosome" enrichment), indicating that these fundamental cellular processes are broadly affected.

Biological Interpretation

The GSEA results reveal distinct and shared pathway alterations across different brain cell types in the E280A and Sporadic conditions, which are highly relevant to neurodegenerative processes.

1. Metabolic Dysfunction and ER Stress: The consistent and significant enrichment of "Oxidative phosphorylation," "Protein processing in endoplasmic reticulum," and "Ribosome" pathways across Astrocytes, Microglia, Neurons, Oligodendrocytes, and OPCs in E280A and Sporadic conditions points to widespread cellular stress. This suggests mitochondrial dysfunction, impaired protein quality control, and increased protein synthesis demands, which are hallmarks of neurodegeneration. Accumulation of misfolded proteins and mitochondrial energy deficits are critical factors in neuronal vulnerability and overall brain health in these diseases PubMed: 35058721.
2. Neuroinflammation and Immune Activation: The enrichment of diverse immune-related pathways ("Antigen processing and presentation," "ECM-receptor interaction," "Focal adhesion," "Pathogenic Escherichia coli infection" and other infection-related pathways) predominantly in Microglia and Astrocytes indicates a strong neuroinflammatory response. Microglial activation is a well-established feature of neurodegenerative diseases, where they can adopt various phenotypes, including pro-inflammatory and phagocytic states GeneCards: MICROGLIA. Changes in ECM-receptor interaction and focal adhesion suggest alterations in cell-matrix interactions and cell migration, crucial for microglial responses and potentially affecting brain tissue integrity.
3. Neuronal Perturbations: The enrichment of the "Synaptic vesicle cycle" in Neurons in disease conditions suggests dysregulation of synaptic function, which is critical for neuronal communication and often an early event in neurodegeneration PubMed: 31737385. The enrichment of the "Huntington disease" pathway, while not directly related to the E280A or Sporadic etiologies provided, might indicate shared molecular mechanisms or cellular vulnerabilities in neurodegenerative processes, given that Huntington's is a canonical neurodegenerative disease involving protein aggregation and neuronal loss.
4. Cell Death and Degradation Pathways: The enrichment of "Apoptosis" and "Autophagy" pathways in Astrocytes and Microglia suggests active mechanisms of programmed cell death and cellular recycling/degradation. While autophagy can be protective, its chronic activation or dysregulation can contribute to pathology. Apoptosis, if uncontrolled, leads to cell loss.
5. MAPK Pathway Downregulation: The general suppression of the "MAPK signaling pathway" in several cell types (Astrocytes, Neurons, OPCs) could have broad implications, as MAPK pathways are involved in cell proliferation, differentiation, stress responses, and survival. Its downregulation might indicate impaired cellular resilience or altered signaling in response to stress.
6. Oligodendrocyte and OPC Vulnerability: The involvement of Oligodendrocytes and OPCs in metabolic and ER stress pathways highlights that not only neurons but also myelin-producing and precursor cells are significantly impacted, which could lead to demyelination or impaired myelination, contributing to white matter pathology often observed in neurodegenerative disorders.

Clinical or Translational Implications

The pervasive metabolic and ER stress signatures across multiple brain cell types represent fundamental cellular vulnerabilities that could be targeted therapeutically. Strategies aimed at improving mitochondrial function, enhancing protein quality control, or reducing ER stress might have broad neuroprotective effects.

The prominent neuroinflammatory signature, particularly in Microglia and Astrocytes, suggests that modulating immune responses could be a viable therapeutic avenue. Targeting specific pro-inflammatory pathways or promoting anti-inflammatory phenotypes in these glial cells might mitigate neurodegeneration. However, the varied response of the Notch pathway in Microglia between E280A and Sporadic conditions suggests that neuroinflammation might manifest differently depending on the specific disease context, requiring precise therapeutic strategies.

Neuronal synaptic dysfunction identified through the "Synaptic vesicle cycle" enrichment indicates that preserving synaptic integrity and function is crucial. Therapeutic approaches focused on improving synaptic health or compensating for synaptic deficits could be beneficial for cognitive and motor symptoms.

Overall, these GSEA results provide a comprehensive overview of the perturbed biological pathways in specific brain cell types under disease conditions, offering a roadmap for further investigation into disease mechanisms and potential therapeutic targets.

14. Discussion

The comprehensive single-cell analysis of human brain tissue from familial (E280A) and sporadic Alzheimer's disease (AD) reveals widespread cellular and molecular dysregulation, highlighting the complex pathology of neurodegeneration. A foundational observation is the clear evidence of astrogliosis, characterized by a significant increase in Astrocyte populations, particularly in sporadic AD, consistent with a reactive state observed in neuroinflammatory conditions. Concurrently, microglial populations exhibit a consistent shift from a homeostatic M0 state towards M2c and M2b-like phenotypes in both E280A and sporadic AD, suggesting a predominant role for immune resolution, phagocytosis, or immunosuppression rather than a classical M1 pro-inflammatory response in these sampled tissues. The relative absence of a dominant M1 microglial response is notable and suggests a nuanced inflammatory landscape or potentially a shift towards a chronic, unresolved inflammatory state.

Cell-cell interaction (CCI) analysis further illuminates the intricate changes in neuro-glial communication. While control brains exhibit robust interactions essential for homeostasis, both E280A and sporadic AD show a significant "re-wiring" of these networks. In E280A, there's a pronounced shift towards microglia-mediated interactions, including integrin-related adhesion, Wnt signaling, and critically, an interaction between APP and SORL1 on microglia and oligodendrocytes. This directly links amyloid pathology to glial responses in familial AD, suggesting microglia and oligodendrocytes are actively involved in sensing and responding to amyloid burden. In contrast, sporadic AD is characterized by profound alterations in neuron-oligodendrocyte communication, involving pathways crucial for myelination (NRG1-integrin) and synaptic organization (PTPRF/S, LRFN, LRRTM, FLRT2, EFNA1/EPHA5). This suggests that white matter integrity and direct neuronal support systems are significantly compromised in sporadic AD, potentially representing distinct primary pathological drivers compared to the more amyloid-driven familial forms.

Furthermore, condition-specific microglial surface markers reveal distinct phenotypes: control microglia express canonical homeostatic markers like CX3CR1, while E280A microglia upregulate vascular/DAM markers such as LYVE1 and OLR1 (oxidized LDL receptor), and sporadic AD microglia show increased CD163 (M2-like) and ESR1 (estrogen receptor 1). These differential surfaceome profiles underscore the distinct functional states adopted by microglia in response to differing AD etiologies, potentially explaining varying inflammatory and homeostatic roles.

At a broader pathway level, Gene Ontology (GSA) and Gene Set Enrichment Analysis (GSEA) consistently demonstrate widespread metabolic dysfunction (oxidative phosphorylation), endoplasmic reticulum stress, and ribosomal enrichment across multiple brain cell types in both AD conditions. Neurons exhibit prominent synaptic dysfunction (synaptic vesicle cycle, glutamatergic/dopaminergic synapse pathways), while glia (especially microglia and astrocytes) show robust immune activation, antigen processing, and ECM remodeling. The downregulation of 14-3-3 proteins (YWHAB, YWHAG, YWHAH) and upregulation of cell cycle components (CCNH, MAD1L1, RB1, STAG1) in AD, particularly sporadic AD, provides strong evidence for aberrant cell cycle re-entry in post-mitotic neurons and impaired cellular resilience, both central to AD pathogenesis. The observation of "Huntington disease" and "Parkinson disease" pathways also being enriched in AD conditions suggests convergent mechanisms or shared vulnerabilities across various neurodegenerative disorders. The unique CD93-IFNGR1 interaction in sporadic AD further hints at subtype-specific immune dysregulation involving the complement system and IFN-gamma signaling. Overall, the data paints a picture of comprehensive cellular stress, re-wired cellular communication, and distinct yet overlapping pathological responses in familial and sporadic Alzheimer's disease.

Hypotheses:

1. Aberrant cell cycle re-entry and subsequent neuronal death in Alzheimer's disease are driven by the downregulation of 14-3-3 proteins (YWHAB, YWHAG, YWHAH) and the upregulation of cell cycle regulators (CCNH, MAD1L1, RB1, STAG1).
2. The distinct microglial surfaceome profiles (e.g., OLR1 in E280A vs. CD163/ESR1 in Sporadic AD) reflect specific functional polarization states that contribute differentially to amyloid clearance, neuroinflammation, and tissue remodeling in familial versus sporadic Alzheimer's disease.
3. The APP-SORL1 interaction between microglia and oligodendrocytes in familial AD, along with increased integrin-mediated interactions, facilitates amyloid plaque formation or exacerbates pathological glial responses, while altered neuron-oligodendrocyte interactions (e.g., NRG1-integrin, PTPRF/S, LRRTM) drive white matter pathology and synaptic dysfunction in sporadic AD.
4. Persistent metabolic dysfunction, ER stress, and impaired protein processing are central, convergent pathological mechanisms across multiple brain cell types in both familial and sporadic Alzheimer's disease, leading to widespread cellular vulnerability and neurodegeneration.

Potential therapeutic targets:

1. OLR1 (Oxidized Low-Density Lipoprotein Receptor 1): Upregulated in E280A microglia, OLR1 is a scavenger receptor involved in binding oxidized LDL and mediating inflammatory responses. Blocking OLR1 could reduce inflammatory lipid uptake and subsequent neuroinflammation. Evidence: OLR1 was identified as a condition-specific surface marker for E280A microglia (Section 10). It is linked to inflammation and AD pathology. Validation: Test OLR1 antagonists or genetic knockdown in E280A cell models (e.g., iPSC-derived microglia) or AD animal models, measuring lipid accumulation, inflammatory cytokine release, and amyloid-beta clearance.
2. 14-3-3 Proteins (e.g., YWHAG, YWHAH): Consistently downregulated in both E280A and Sporadic AD, these proteins are crucial adaptors involved in cell cycle control, apoptosis, and protein trafficking, notably interacting with tau. Restoring their function could mitigate tau pathology and cellular dysfunction. Evidence: Significant downregulation of YWHAG and YWHAH was observed in E280A and Sporadic AD brains, with a progressive decrease in YWHAH (Section 11). They are known to interact with tau and play a role in AD pathology. Validation: Investigate the effect of agents that increase 14-3-3 protein expression or activity in AD cell lines or mouse models. Assess impacts on tau phosphorylation, aggregation, neuronal survival, and cell cycle re-entry.
3. TGFB signaling pathway: Intensified and widespread TGFB signaling observed across neuro-glial cells in both E280A and Sporadic AD, indicating increased glial activation and neuroinflammation. Modulating this pathway could alleviate excessive neuroinflammation. Evidence: Prominent and intensified TGFB signaling, especially between Neuron-Microglia and Neuron-Astrocyte, was observed in E280A and Sporadic conditions (Section 8). Validation: Test TGFB receptor inhibitors or modulators in AD models to assess their effect on microglial activation states, astrocyte reactivity, inflammatory cytokine profiles, and neuronal health. Careful titration would be required given its pleiotropic role.
4. APP-SORL1 interaction: Identified as a specific interaction between microglia and oligodendrocytes in E280A AD, directly linking amyloid-beta precursor protein to SORL1, a regulator of APP trafficking and Aβ clearance. Disrupting pathological APP-SORL1 interactions could reduce amyloid burden or modulate glial responses. Evidence: APP-SORL1 interaction was detected between Microglia and Oligodendrocyte in the E280A condition (Section 9). Validation: Develop small molecules or antibodies to block this specific ligand-receptor interaction in familial AD cell models or transgenic mouse models, and assess effects on amyloid plaque formation, microglial phagocytosis, and oligodendrocyte function.

Follow-up validation ideas:

1. Spatial Transcriptomics/Proteomics: To validate the identified cell-cell interaction patterns and condition-specific marker expression in situ, investigating their spatial distribution and co-localization within brain tissue sections. This would confirm whether the inferred interactions and cell states are physically manifest and spatially organized.
2. Flow Cytometry or Immunostaining: To quantify and localize the expression of key microglial surface markers (e.g., CX3CR1, OLR1, CD163, ESR1, LYVE1) on isolated microglia or in brain sections from larger patient cohorts, confirming the phenotypic shifts and their prevalence.
3. Perturbation Assays in iPSC-derived Organoids/Co-cultures: To functionally validate the impact of altered cell-cell interactions (e.g., APP-SORL1, NRG1-integrin, TGFB signaling) by overexpressing or knocking down specific ligands/receptors in human iPSC-derived neuron-glial co-cultures or brain organoids, and assessing downstream effects on synaptic health, neuroinflammation, and cell survival.
4. Targeted qPCR/Western Blotting: To confirm the differential expression of key cell cycle genes (CCNH, MAD1L1, RB1, STAG1, SKP1, YWHAB, YWHAG, YWHAH) and 14-3-3 proteins at the mRNA and protein levels in bulk brain tissue or sorted cell populations from independent AD cohorts.
5. Functional Assays for Microglia: To assess the phagocytic capacity, inflammatory cytokine production, and migratory activity of AD-derived microglia (or iPSC-derived microglia) in response to amyloid-beta or other AD-related stimuli, correlating these functions with the observed surfaceome and pathway changes.
6. Validation in Animal Models: To investigate the functional consequences of modulating identified pathways (e.g., TGFB, EGF/EGFR, specific cell cycle regulators) in AD mouse models on disease progression, neuropathology, and cognitive function.
7. Clinical Cohort Replication: To replicate the identified cell type population shifts and gene expression changes in larger, independent single-cell or bulk RNA-seq cohorts of familial and sporadic AD patients to ensure generalizability.

Limitations:

This study is based on post-mortem human brain tissue, which introduces limitations related to post-mortem interval effects and the analysis of end-stage disease pathology. The cross-sectional design prevents inference of causality or dynamic disease progression. While single-cell RNA-seq provides high resolution, it reflects a snapshot of gene expression and does not fully capture protein levels, post-translational modifications, or direct cellular functions. Inferred cell-cell interactions are computational predictions requiring experimental validation. Furthermore, the presence of 'unassigned' cell clusters warrants further investigation to fully characterize potentially novel or ambiguous cell populations. The observed sample-specific variability, or batch effects, highlights the need for careful statistical correction and validation in larger, more diverse cohorts.

15. Query List

1. Show UMAPs with condition, sample, major cell type, minor cell type, and celltype_subset annotations in 2 columns and save.
2. Show expression of CD3D CD4 CD8A CD79A MS4A1 MZB1 CD14 LYZ FBLN1 NOTCH3 EPCAM MUC1 CD34 genes on UMAP along with minor cell type annotation. Set ncols=4 and save.
3. Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
4. Show a population bar plot for minor cell types and save.
5. Show a subset population barplot for Microglia and save.
6. Show boxplots for Microglia subset populations, highlighting statistically significant differences between conditions, and save. Set ncols appropriately based on the total number of panels.
7. Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
8. Show cell-cell interactions for genes related to immune checkpoint and cell cycle pathways, and save.
9. Find statistically significant differences in cell-cell interactions between conditions for Microglia, Astrocyte, and Oligodendrocyte, and show them as a dot plot and save. Set max_n_items_per_group = 25.
10. Extract condition-specific markers for Microglia and show them as a dot plot and save. Include only surfaceome markers, up to 50 per condition.
11. Show boxplots of statistically significant differential expression of cell cycle pathway-related genes across conditions for Astrocyte, Microglia, Neuron, Oligodendrocyte, and Oligodendrocyte progenitor cell, and save. Set max_n_items_to_plot = 24, and ncols appropriately to achieve an approximate 2x3 aspect ratio.
12. Show Gene Ontology (GSA) analysis results as a bar plot for Astrocyte, Microglia, Neuron, Oligodendrocyte, and Oligodendrocyte progenitor cell and save.
13. Show Gene Set Enrichment Analysis results as a dot plot for Astrocyte, Microglia, Neuron, Oligodendrocyte, and Oligodendrocyte progenitor cell and save. Use RdBu_r as the color map and set n_pws_to_show = 80.